Stock analysis searches answered, part 19 of 43

Arcus biosciences rcus gilead cash runway latest news

For “Arcus biosciences rcus gilead cash runway latest news”, the matching SEC registrant is Arcus Biosciences, Inc., which trades as RCUS and files under Central Index Key 1724521. EDGAR puts it in the “Pharmaceutical Preparations” industry code with DE as its state or country of incorporation. Data below comes straight from EDGAR as checked on Oct 25, 2026, where the latest item is a 8-K filed 2026-10-23, across 607 filings on record. This is reference material, not trading advice.

Business description, quoted from the 10-K filed 2026-02-25 by Arcus Biosciences, Inc. (CIK 1724521) — source document:

We are a late clinical-stage biopharmaceutical company focused on developing differentiated molecules for patients with cancer and inflammatory and autoimmune diseases. Our most advanced molecules are in Phase 3 registrational studies for various cancer indications and we expect our next wave of clinical-stage molecules to come from our inflammation and autoimmune disease programs. Our vision is to leverage our internal small-molecule discovery capabilities to create, develop and commercialize highly differentiated therapies that can have a meaningful impact on patients. The chart below summarizes our current clinical and late pre-clinical stage portfolio: * Taiho holds exclusive licenses in Japan and certain other Asian countries, excluding China, for casdatifan (the “Taiho Territory”). † Gilead and Arcus co-develop globally and share co-promotion rights in the U.S. for domvanalimab and quemliclustat.

Financial trend for Arcus Biosciences, Inc. from annual reports, periods 2022-12-31 to 2025-12-31: revenue went from $112.00 million (2022-12-31) to $247.00 million (2025-12-31), a change of +120.5%; net income (loss) went from -$267.00 million (2022-12-31) to -$353.00 million (2025-12-31), a change of -32.2%; total assets went from $1.34 billion (2022-12-31) to $1.14 billion (2025-12-31), a change of -15.3%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 1724521, tags Assets, NetIncomeLoss, Revenues; 4 periods shown, dashes mark figures Arcus Biosciences, Inc. did not tag for that period.

For the latest news, the fastest official source is the filing feed: Arcus Biosciences, Inc. (CIK 1724521) filed 95 current reports (8-K or 6-K) in its recent EDGAR window, the newest on 2026-10-23, and its overall latest filing is a 8-K dated 2026-10-23. Companies must file an 8-K within four business days of most material events.

Current reports. Of the 95 8-K or 6-K reports in Arcus Biosciences, Inc.’s recent EDGAR index, the 4 listed here run from 2026-08-05 to 2026-10-23, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 1724521 is on the EDGAR company page; the latest 10-K there is dated 2026-02-25 and the oldest filing in the recent index dates from 2017-12-15. Insider trades for Arcus Biosciences, Inc. appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Ars rei sl outlook

Also searched as: ars rei sl outlook -site:x.com -site:twitter.com -site:facebook.com -site:instagram.com -site:tiktok.com -site:youtube.com -site:linkedin.com

What this search refers to. “Ars Rei SL” is a Spanish company form (Sociedad Limitada, a private limited company); Spanish companies’ accounts are filed with the Registro Mercantil. Official source: www.registradores.org.

No SEC filer could be matched to “Ars rei sl outlook” with a single, clear Central Index Key: neither EDGAR’s company index nor its full-text search (phrase “Ars rei sl”) returns a registrant with this name. Rather than show another company’s numbers, this section explains what the official record does and does not contain for the term “ars” (search terms considered: ars, rei, outlook).

EDGAR’s company index has 61 entities whose registered name contains the word “ars”; the first few are shown below so you can see whether any is the business you mean. None of them matches the full search wording closely enough to be treated as the same company.

Word by word, the number of EDGAR registrant names containing each term of this search is: “ars” 61, “rei” 94, “outlook” 29. A term that appears in many unrelated names is a weak identifier on its own, which is why this page does not attach any one filer’s financial data to the query.

Sample EDGAR registrant names, term by term — containing “ars”: ARS ALTERNATIVE INVESTMENT FUND LLC (CIK 1818993), ARS GLOBAL,INC. (CIK 1555332), ARS INVESTMENT PARTNERS, LLC (CIK 733020); containing “rei”: 4M REI FUND I, LLC (CIK 1859687), 4M REI FUND II, LLC (CIK 1933880), ALIST PARTNERS REI FUND I, LLC (CIK 1638461); containing “outlook”: CENTURY AT OUTLOOK, LLC (CIK 1627734), CLIENT OUTLOOK INC. (CIK 1531146), EC OUTLOOK INC (CIK 1170030). These are listed only to show how the individual words map onto unrelated filers; none should be read as the subject of the search.

For this particular search: analyst views on “ars” are third-party opinions; the SEC neither issues nor reviews ratings, so check any rating against the company’s own annual report. If the business says it is registered but does not appear in EDGAR or on FINRA BrokerCheck, treat that as a red flag. This page offers no buy or sell recommendation.

Updated Oct 25, 2026 ET

Asbury automotive group abg latest news october 2026

For “Asbury automotive group abg latest news october 2026”, the matching SEC registrant is ASBURY AUTOMOTIVE GROUP INC, which trades as ABG and files under Central Index Key 1144980. EDGAR puts it in the “Retail-Auto Dealers & Gasoline Stations” industry code with DE as its state or country of incorporation. Data below comes straight from EDGAR as checked on Oct 25, 2026, where the latest item is a SCHEDULE 13G/A filed 2026-10-08, across 1000 filings on record. This is reference material, not trading advice.

Business description, quoted from the 10-K filed 2026-02-20 by ASBURY AUTOMOTIVE GROUP INC (CIK 1144980) — source document:

Asbury Automotive Group, Inc., a Delaware corporation organized in 2002, is a Fortune 500 company and one of the largest franchised automotive retailers in the United States. Our mission is to put the guest experience first and follow our "North Star," i.e., to be the most guest-centric automotive retailer in the industry. We follow three key principles to guide us: (1) have a fun, supportive and inclusive culture where team members thrive personally while building meaningful bonds with one another; (2) be great brand ambassadors and exceptional stewards of capital for our partners who fuel our mission; and (3) be caring professionals who strive to delight our guests and foster love for the brand.

Financial trend for ASBURY AUTOMOTIVE GROUP INC from annual reports, periods 2022-12-31 to 2025-12-31: revenue went from $15.43 billion (2022-12-31) to $18.00 billion (2025-12-31), a change of +16.6%; net income (loss) went from $997.30 million (2022-12-31) to $492.00 million (2025-12-31), a change of -50.7%; total assets went from $8.02 billion (2022-12-31) to $11.62 billion (2025-12-31), a change of +44.8%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 1144980, tags Assets, NetIncomeLoss, Revenues; 4 periods shown, dashes mark figures ASBURY AUTOMOTIVE GROUP INC did not tag for that period.

For the latest news, the fastest official source is the filing feed: ASBURY AUTOMOTIVE GROUP INC (CIK 1144980) filed 150 current reports (8-K or 6-K) in its recent EDGAR window, the newest on 2026-08-31, and its overall latest filing is a SCHEDULE 13G/A dated 2026-10-08. Companies must file an 8-K within four business days of most material events.

Current reports. Of the 150 8-K or 6-K reports in ASBURY AUTOMOTIVE GROUP INC’s recent EDGAR index, the 4 listed here run from 2026-05-06 to 2026-08-31, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 1144980 is on the EDGAR company page; the latest 10-K there is dated 2026-02-20 and the oldest filing in the recent index dates from 2014-01-10. Insider trades for ASBURY AUTOMOTIVE GROUP INC appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Atyr pharma, inc. bullish and bearish analyst opinions

For “Atyr pharma, inc. bullish and bearish analyst opinions”, the matching SEC registrant is aTYR PHARMA INC, which trades as ATYR and files under Central Index Key 1339970. EDGAR puts it in the “Biological Products, (No Diagnostic Substances)” industry code with DE as its state or country of incorporation. Data below comes straight from EDGAR as checked on Oct 25, 2026, where the latest item is a 8-K filed 2026-10-16, across 749 filings on record. This is reference material, not trading advice.

Financial trend for aTYR PHARMA INC from annual reports, periods 2022-12-31 to 2025-12-31: revenue went from $10.39 million (2022-12-31) to $190,000 (2025-12-31), a change of -98.2%; net income (loss) went from -$45.34 million (2022-12-31) to -$74.12 million (2025-12-31), a change of -63.5%; total assets went from $95.79 million (2022-12-31) to $93.00 million (2025-12-31), a change of -2.9%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 1339970, tags Assets, NetIncomeLoss, RevenueFromContractWithCustomerExcludingAssessedTax; 4 periods shown, dashes mark figures aTYR PHARMA INC did not tag for that period.

Analyst ratings, price targets and “bullish” or “bearish” calls on aTYR PHARMA INC (CIK 1339970) are third-party opinions that the SEC does not publish or check. What the regulator does hold are the facts those views are built on: the latest results release filed under 8-K Item 2.02 is dated 2026-08-07, and the most recent 10-K annual report was filed 2026-03-05. Comparing any rating with those primary documents shows whether the thesis matches what the company itself reported.

Current reports. Of the 141 8-K or 6-K reports in aTYR PHARMA INC’s recent EDGAR index, the 4 listed here run from 2026-07-31 to 2026-10-16, with the item codes the company selected and what each code covers under SEC rules.

Other filings. Across its 749 recent EDGAR filings, aTYR PHARMA INC most often filed 4 (281), 8-K (141), SC 13G/A (46), 3 (43). A selection from 2026-08-31 to 2026-10-07:

The full record for CIK 1339970 is on the EDGAR company page; the latest 10-K there is dated 2026-03-05 and the oldest filing in the recent index dates from 2005-09-23. Insider trades for aTYR PHARMA INC appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Aviat networks latest news october 2026 product partnership

For “Aviat networks latest news october 2026 product partnership”, the matching SEC registrant is AVIAT NETWORKS, INC., which trades as AVNW and files under Central Index Key 1377789. EDGAR puts it in the “Radio & Tv Broadcasting & Communications Equipment” industry code with DE as its state or country of incorporation; its earlier registered name was Aviat Networks Inc. Data below comes straight from EDGAR as checked on Oct 25, 2026, where the latest item is a 4 filed 2026-10-13, across 1000 filings on record. This is reference material, not trading advice.

Business description, quoted from the 10-K filed 2026-08-27 by AVIAT NETWORKS, INC. (CIK 1377789) — source document:

Aviat Networks, Inc., together with its subsidiaries, is a global supplier of microwave networking and wireless access networking solutions, backed by an extensive suite of professional services and support. Aviat Networks, Inc. may be referred to as “the Company,” “AVNW,” “Aviat Networks,” “Aviat,” “we,” “us” and “our” in this Annual Report on Form 10-K. Aviat was incorporated in Delaware in 2006 to combine the businesses of Harris Corporation’s Microwave Communications Division (“MCD”) and Stratex Networks, Inc. (“Stratex”). On January 28, 2010, we changed our corporate name from Harris Stratex Networks, Inc. to Aviat Networks, Inc. Aviat’s principal executive offices are located at 200C Parker Dr., Suite 100A, Austin, Texas 78728, and its telephone number is (512) 265-3680.

Financial trend for AVIAT NETWORKS, INC. from annual reports, periods 2023-06-30 to 2026-07-03: net income (loss) went from $10.17 million (2023-06-30) to $2.54 million (2026-07-03), a change of -75.0%; total assets went from $363.14 million (2023-06-30) to $598.96 million (2026-07-03), a change of +64.9%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 1377789, tags Assets, NetIncomeLoss, Revenues; 4 periods shown, dashes mark figures AVIAT NETWORKS, INC. did not tag for that period.

For the latest news, the fastest official source is the filing feed: AVIAT NETWORKS, INC. (CIK 1377789) filed 246 current reports (8-K or 6-K) in its recent EDGAR window, the newest on 2026-10-06, and its overall latest filing is a 4 dated 2026-10-13. Companies must file an 8-K within four business days of most material events.

Current reports. Of the 246 8-K or 6-K reports in AVIAT NETWORKS, INC.’s recent EDGAR index, the 4 listed here run from 2026-08-27 to 2026-10-06, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 1377789 is on the EDGAR company page; the latest 10-K there is dated 2026-08-27 and the oldest filing in the recent index dates from 2010-01-28. Insider trades for AVIAT NETWORKS, INC. appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Balchem corp bullish and bearish analyst opinions

For “Balchem corp bullish and bearish analyst opinions”, the matching SEC registrant is BALCHEM CORP, which trades as BCPC and files under Central Index Key 9326. EDGAR puts it in the “Chemicals & Allied Products” industry code with MD as its state or country of incorporation. Data below comes straight from EDGAR as checked on Oct 25, 2026, where the latest item is a 10-Q filed 2026-10-23, across 1001 filings on record. This is reference material, not trading advice.

Business description, quoted from the 10-K filed 2026-02-20 by BALCHEM CORP (CIK 9326) — source document:

We develop, manufacture, distribute and market specialty performance ingredients and products for the nutritional, food, pharmaceutical, animal health, plant nutrition, sterilization, fumigation, and industrial markets. Our three reportable segments are strategic businesses that offer products and services to different markets: Human Nutrition and Health, Animal Nutrition and Health, and Specialty Products. Sales and production of products outside of our reportable segments and other minor business activities are included in "Other and Unallocated". We sell our products through our own sales force, independent distributors and sales agents. Human Nutrition and Health The Human Nutrition and Health ("HNH") segment provides human grade choline nutrients and mineral amino acid chelated products for nutrition and health applications.

Financial trend for BALCHEM CORP from annual reports, periods 2022-12-31 to 2025-12-31: net income (loss) went from $105.37 million (2022-12-31) to $154.84 million (2025-12-31), a change of +47.0%; total assets went from $1.62 billion (2022-12-31) to $1.69 billion (2025-12-31), a change of +3.8%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 9326, tags Assets, NetIncomeLoss, Revenues; 4 periods shown, dashes mark figures BALCHEM CORP did not tag for that period.

Analyst ratings, price targets and “bullish” or “bearish” calls on BALCHEM CORP (CIK 9326) are third-party opinions that the SEC does not publish or check. What the regulator does hold are the facts those views are built on: the latest results release filed under 8-K Item 2.02 is dated 2026-10-23, and the most recent 10-K annual report was filed 2026-02-20. Comparing any rating with those primary documents shows whether the thesis matches what the company itself reported.

Current reports. Of the 162 8-K or 6-K reports in BALCHEM CORP’s recent EDGAR index, the 4 listed here run from 2026-06-22 to 2026-10-23, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 9326 is on the EDGAR company page; the latest 10-K there is dated 2026-02-20 and the oldest filing in the recent index dates from 2008-01-16. Insider trades for BALCHEM CORP appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Barnwell industries, inc. bullish and bearish analyst opinions

For “Barnwell industries, inc. bullish and bearish analyst opinions”, the matching SEC registrant is BARNWELL INDUSTRIES INC, which trades as BRN and files under Central Index Key 10048. EDGAR puts it in the “Crude Petroleum & Natural Gas” industry code with DE as its state or country of incorporation. Data below comes straight from EDGAR as checked on Oct 25, 2026, where the latest item is a 8-K filed 2026-10-19, across 1000 filings on record. This is reference material, not trading advice.

Business description, quoted from the 10-K filed 2025-12-23 by BARNWELL INDUSTRIES INC (CIK 10048) — source document:

Barnwell was incorporated in Delaware in 1956 and fiscal 2025 represented Barnwell’s 69th year of operations. Barnwell operates in the following two principal business segments: • Oil and Natural Gas Segment - Barnwell engages in oil and natural gas development, production, acquisitions and sales in Canada and in the U.S. • Land Investment Segment - Barnwell owns land interests in the State of Hawaii. Discontinued Operations On March 14, 2025, the Company entered into and completed the sale of its wholly-owned subsidiary, Water Resources International, Inc. (“Water Resources”). Water Resources drills water wells and installs and repairs water pumping systems in the State of Hawaii and represented Barnwell's contract drilling segment.

Financial trend for BARNWELL INDUSTRIES INC from annual reports, periods 2022-09-30 to 2025-09-30: revenue went from $28.55 million (2022-09-30) to $13.70 million (2025-09-30), a change of -52.0%; net income (loss) went from $5.51 million (2022-09-30) to -$7.10 million (2025-09-30), a change of -228.8%; total assets went from $37.22 million (2022-09-30) to $20.81 million (2025-09-30), a change of -44.1%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 10048, tags Assets, NetIncomeLoss, Revenues; 4 periods shown, dashes mark figures BARNWELL INDUSTRIES INC did not tag for that period.

Analyst ratings, price targets and “bullish” or “bearish” calls on BARNWELL INDUSTRIES INC (CIK 10048) are third-party opinions that the SEC does not publish or check. What the regulator does hold are the facts those views are built on: the latest results release filed under 8-K Item 2.02 is dated 2026-08-12, and the most recent 10-K annual report was filed 2025-12-23. Comparing any rating with those primary documents shows whether the thesis matches what the company itself reported.

Current reports. Of the 211 8-K or 6-K reports in BARNWELL INDUSTRIES INC’s recent EDGAR index, the 4 listed here run from 2026-09-16 to 2026-10-19, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 10048 is on the EDGAR company page; the latest 10-K there is dated 2025-12-23 and the oldest filing in the recent index dates from 2002-08-14. Insider trades for BARNWELL INDUSTRIES INC appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Bausch health bhc latest news october 2026

For “Bausch health bhc latest news october 2026”, the matching SEC registrant is Bausch Health Companies Inc., which trades as BHC and files under Central Index Key 885590. EDGAR puts it in the “Pharmaceutical Preparations” industry code with NJ as its state or country of incorporation; its earlier registered name was Valeant Pharmaceuticals International, Inc. Data below comes straight from EDGAR as checked on Oct 25, 2026, where the latest item is a 4 filed 2026-10-02, across 1002 filings on record. This is reference material, not trading advice.

Business description, quoted from the 10-K filed 2026-02-19 by Bausch Health Companies Inc. (CIK 885590) — source document:

Bausch Health Companies Inc. (“we”, “us”, “our”, the “Company” or “Bausch Health”) is a global, diversified specialty pharmaceutical and medical device company that develops, manufactures and markets, primarily in the therapeutic areas of gastroenterology (“GI”), hepatology, neurology and dermatology, a broad range of branded, generic and branded generic pharmaceuticals, over-the-counter (“OTC”) products and aesthetic medical devices and, through our approximately 88% ownership of Bausch + Lomb Corporation (“Bausch + Lomb” or “B+L”), branded, and branded generic pharmaceuticals, OTC products and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment) in the therapeutic areas of eye health. The Company’s products are marketed directly or indirectly in approximately 90 countries. Our portfolio of products falls into five reportable segments: (i) Salix, (ii) International, (iii) Solta Medical, (iv) Diversified and (v) Bausch + Lomb.

Financial trend for Bausch Health Companies Inc. from annual reports, periods 2022-12-31 to 2025-12-31: net income (loss) went from -$225.00 million (2022-12-31) to $157.00 million (2025-12-31), a change of +169.8%; total assets went from $25.69 billion (2022-12-31) to $26.37 billion (2025-12-31), a change of +2.6%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 885590, tags Assets, NetIncomeLoss, Revenues; 4 periods shown, dashes mark figures Bausch Health Companies Inc. did not tag for that period.

For the latest news, the fastest official source is the filing feed: Bausch Health Companies Inc. (CIK 885590) filed 194 current reports (8-K or 6-K) in its recent EDGAR window, the newest on 2026-07-29, and its overall latest filing is a 4 dated 2026-10-02. Companies must file an 8-K within four business days of most material events.

Current reports. Of the 194 8-K or 6-K reports in Bausch Health Companies Inc.’s recent EDGAR index, the 4 listed here run from 2026-04-29 to 2026-07-29, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 885590 is on the EDGAR company page; the latest 10-K there is dated 2026-02-19 and the oldest filing in the recent index dates from 2016-05-04. Insider trades for Bausch Health Companies Inc. appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Binah capital group, inc. bullish and bearish analyst opinions

For “Binah capital group, inc. bullish and bearish analyst opinions”, the matching SEC registrant is Binah Capital Group, Inc., which trades as BCG, BCGWW and files under Central Index Key 1953984. EDGAR puts it in the “Finance Services” industry code with an unstated jurisdiction as its state or country of incorporation. Data below comes straight from EDGAR as checked on Oct 25, 2026, where the latest item is a 4 filed 2026-09-09, across 102 filings on record. This is reference material, not trading advice.

Business description, quoted from the 10-K filed 2026-03-31 by Binah Capital Group, Inc. (CIK 1953984) — source document:

Binah Capital Group, Inc. is a Delaware corporation with its corporate headquarters located at 80 State Street, Albany, NY 12207, telephone number (212) 404-7002, Internet website address www.binahcap.com. Our Internet website and content contained therein or connected thereto are not intended to incorporate into this Annual Report. References to “Binah,” the “Company,” “we,” “our” and “us” and similar terms mean Binah Capital Group, Inc. and its subsidiaries following the completion of the Business Combination (as defined below), unless the context otherwise requires. The Business Combination On March 15, 2024 (the “ Closing Date ”), the Company consummated the transactions contemplated by that certain Agreement and Plan of Merger, dated July 7, 2022 (as amended, the “ Business Combination Agreement ” and the consummation of such contemplated transactions, the “ Closing ”), by and among Kingswood Acquisition Corp, a Delaware corporation (“ KWAC ”), the Company, Kingswood Merger Sub, Inc., a Delaware corporation (“ Kingswood Merger Sub ”), Wentworth Merger Sub, LLC, a Delaware limited liability company (“ Wentworth Merger Sub ”), and Wentworth Management Services LLC, a Delaware limited liability company (“ Wentworth ”).

Financial trend for Binah Capital Group, Inc. from annual reports, periods 2023-12-31 to 2025-12-31: revenue went from $167.96 million (2023-12-31) to $187.14 million (2025-12-31), a change of +11.4%; net income (loss) went from $571,000 (2023-12-31) to $2.31 million (2025-12-31), a change of +304.2%; total assets went from $67.41 million (2023-12-31) to $70.22 million (2025-12-31), a change of +4.2%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 1953984, tags Assets, NetIncomeLoss, Revenues; 3 periods shown, dashes mark figures Binah Capital Group, Inc. did not tag for that period.

Analyst ratings, price targets and “bullish” or “bearish” calls on Binah Capital Group, Inc. (CIK 1953984) are third-party opinions that the SEC does not publish or check. What the regulator does hold are the facts those views are built on: the latest results release filed under 8-K Item 2.02 is dated 2026-08-14, and the most recent 10-K annual report was filed 2026-03-31. Comparing any rating with those primary documents shows whether the thesis matches what the company itself reported.

Current reports. Of the 18 8-K or 6-K reports in Binah Capital Group, Inc.’s recent EDGAR index, the 4 listed here run from 2026-05-15 to 2026-08-20, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 1953984 is on the EDGAR company page; the latest 10-K there is dated 2026-03-31 and the oldest filing in the recent index dates from 2022-12-23. Insider trades for Binah Capital Group, Inc. appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Black spade acquisition iii co bullish and bearish analyst opinions

For “Black spade acquisition iii co bullish and bearish analyst opinions”, the matching SEC registrant is Black Spade Acquisition III Co, which trades as BIII, BIII-UN, BIII-WT and files under Central Index Key 2087087. EDGAR puts it in the “Communications Services, NEC” industry code with Hong Kong as its state or country of incorporation. Data below comes straight from EDGAR as checked on Oct 25, 2026, where the latest item is a F-4 filed 2026-10-15, across 44 filings on record. This is reference material, not trading advice.

Business description, quoted from the 10-K filed 2026-03-06 by Black Spade Acquisition III Co (CIK 2087087) — source document:

We are a blank check company incorporated under the laws of the Cayman Islands as an exempted company with limited liability for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses or assets, which we refer to throughout this Annual Report as our initial business combination. While we may pursue an initial business combination opportunity in any business or industry, we are focused on identifying a business combination target that can benefit from the extensive collective network, knowledge and experience of our founder and management team that is related to or in the entertainment industry, with a focus on enabling technology, lifestyle brands, products, or services and entertainment media (the “Target Sectors”).

Financial trend for Black Spade Acquisition III Co from quarterly and annual reports (three-month periods), periods 2026-03-31 to 2026-06-30: net income (loss) went from $1.09 million (2026-03-31) to $848,429 (2026-06-30), a change of -22.0%; total assets went from $174.82 million (2026-03-31) to $176.22 million (2026-06-30), a change of +0.8%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 2087087, tags Assets, NetIncomeLoss; 2 periods shown, dashes mark figures Black Spade Acquisition III Co did not tag for that period.

Analyst ratings, price targets and “bullish” or “bearish” calls on Black Spade Acquisition III Co (CIK 2087087) are third-party opinions that the SEC does not publish or check. What the regulator does hold are the facts those views are built on, and the most recent 10-K annual report was filed 2026-03-06. Comparing any rating with those primary documents shows whether the thesis matches what the company itself reported.

Deal and listing documents for Black Spade Acquisition III Co — registration statements, prospectuses and merger proxies — are filed on EDGAR; 9 such filings (424B3, 425, F-4, S-1, S-1/A) appear in its recent index, the newest dated 2026-10-15.

Current reports. Of the 4 8-K or 6-K reports in Black Spade Acquisition III Co’s recent EDGAR index, the 4 listed here run from 2026-01-09 to 2026-08-27, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 2087087 is on the EDGAR company page; the latest 10-K there is dated 2026-03-06 and the oldest filing in the recent index dates from 2025-09-30. Insider trades for Black Spade Acquisition III Co appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Bridgebio oncology therapeutics bbot leadership executive board october 2026

For “Bridgebio oncology therapeutics bbot leadership executive board october 2026”, the matching SEC registrant is BridgeBio Oncology Therapeutics, Inc., which trades as BBOT and files under Central Index Key 1869105. EDGAR puts it in the “Pharmaceutical Preparations” industry code with DE as its state or country of incorporation; its earlier registered name was Helix Acquisition Corp. II. Data below comes straight from EDGAR as checked on Oct 25, 2026, where the latest item is a 4 filed 2026-10-23, across 184 filings on record. This is reference material, not trading advice.

Financial trend for BridgeBio Oncology Therapeutics, Inc. from annual reports, periods 2023-12-31 to 2025-12-31: net income (loss) went from -$41,692 (2023-12-31) to -$134.04 million (2025-12-31), a change of -321410.1%; total assets went from $332,894 (2023-12-31) to $448.38 million (2025-12-31), a change of +134591.8%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 1869105, tags Assets, NetIncomeLoss; 3 periods shown, dashes mark figures BridgeBio Oncology Therapeutics, Inc. did not tag for that period.

BridgeBio Oncology Therapeutics, Inc. has 184 filings in its recent EDGAR index, including 2 annual reports and 8 quarterly reports; its newest filing is a 4 from 2026-10-23.

Current reports. Of the 19 8-K or 6-K reports in BridgeBio Oncology Therapeutics, Inc.’s recent EDGAR index, the 4 listed here run from 2026-05-12 to 2026-09-08, with the item codes the company selected and what each code covers under SEC rules.

Other filings. Across its 184 recent EDGAR filings, BridgeBio Oncology Therapeutics, Inc. most often filed 4 (48), 3 (21), 8-K (19), 424B3 (12). A selection from 2026-10-05 to 2026-10-23:

The full record for CIK 1869105 is on the EDGAR company page; the latest 10-K there is dated 2026-03-05 and the oldest filing in the recent index dates from 2023-12-20. Insider trades for BridgeBio Oncology Therapeutics, Inc. appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Btg hotels (group) co., ltd. bullish and bearish analyst opinions

The legal-form ending in “Btg hotels (group) co., ltd.” is the clue: “Co., Ltd.” is the English rendering used by limited companies across East Asia. A company of that kind reports in China, Taiwan, Korea or Japan, so the place to read its annual report and announcements is the home-exchange disclosure system (SSE/SZSE in mainland China, MOPS in Taiwan, DART in Korea, EDINET in Japan) — mops.twse.com.tw.

No SEC filer could be matched to “Btg hotels (group) co., ltd. bullish and bearish analyst opinions” with a single, clear Central Index Key: the phrase “Btg hotels group co., ltd.” appears in 6221+ EDGAR full-text search results, but those hits do not point to one clearly identifiable issuer with its own CIK. Rather than show another company’s numbers, this section explains what the official record does and does not contain for the term “btg” (search terms considered: btg, hotels).

Even the shorter phrase “Btg hotels co.” returns no EDGAR full-text hits, so no SEC filing since 2001 mentions it; the terms in this search (btg, hotels) point to a business outside the SEC system or one known by another legal name.

In the 100 most relevant full-text hits returned for “Btg hotels group co., ltd.”, filings range from 2015-06-11 to 2024-06-17. The filers whose documents mention it most often are Homeinns Hotel Group (CIK 0001376972) (31 hits); T. Rowe Price International Funds, Inc. (CIK 0000313212) (18 hits); MATTHEWS INTERNATIONAL FUNDS (CIK 0000923184) (12 hits); Global X Funds (CIK 0001432353) (12 hits). A mention in another company’s filing — as a customer, supplier, lender, fund holding or deal counterparty — does not make that filer the company you searched for.

EDGAR’s company index has 60 entities whose registered name contains the word “btg”; the first few are shown below so you can see whether any is the business you mean. None of them matches the full search wording closely enough to be treated as the same company.

Word by word, the number of EDGAR registrant names containing each term of this search is: “btg” 60, “hotels” 219. A term that appears in many unrelated names is a weak identifier on its own, which is why this page does not attach any one filer’s financial data to the query.

For this particular search: analyst views on “btg” are third-party opinions; the SEC neither issues nor reviews ratings, so check any rating against the company’s own annual report. If the business says it is registered but does not appear in EDGAR or on FINRA BrokerCheck, treat that as a red flag. This page offers no buy or sell recommendation.

Updated Oct 25, 2026 ET

Cardinal infrastructure group cdnl latest news

For “Cardinal infrastructure group cdnl latest news”, the matching SEC registrant is Cardinal Infrastructure Group Inc., which trades as CDNL and files under Central Index Key 2079999. EDGAR puts it in the “Heavy Construction Other Than Bldg Const - Contractors” industry code with DE as its state or country of incorporation; its earlier registered name was Civil Infrastructure Group Inc. Data below comes straight from EDGAR as checked on Oct 25, 2026, where the latest item is a SCHEDULE 13G filed 2026-10-19, across 99 filings on record. This is reference material, not trading advice.

Updated Oct 25, 2026 ET

Cardinal infrastructure group cdnl october 2026 news

For “Cardinal infrastructure group cdnl october 2026 news”, the matching SEC registrant is Cardinal Infrastructure Group Inc., which trades as CDNL and files under Central Index Key 2079999. EDGAR puts it in the “Heavy Construction Other Than Bldg Const - Contractors” industry code with DE as its state or country of incorporation; its earlier registered name was Civil Infrastructure Group Inc. Data below comes straight from EDGAR as checked on Oct 25, 2026, where the latest item is a SCHEDULE 13G filed 2026-10-19 (this view begins at filings dated on or before 2026-08-17), across 99 filings on record. This is reference material, not trading advice.

Financial trend for Cardinal Infrastructure Group Inc. from quarterly and annual reports (three-month periods), periods 2025-06-30 to 2026-06-30: revenue went from $106.11 million (2025-06-30) to $226.93 million (2026-06-30), a change of +113.9%; net income (loss) went from $7.17 million (2025-06-30) to $4.68 million (2026-06-30), a change of -34.8%; total assets went from $657.25 million (2026-03-31) to $1.01 billion (2026-06-30), a change of +54.4%. Values are as filed and not adjusted for restatements, splits or currency.

Current reports. Of the 11 8-K or 6-K reports in Cardinal Infrastructure Group Inc.’s recent EDGAR index, the 4 listed here run from 2026-03-18 to 2026-06-05, with the item codes the company selected and what each code covers under SEC rules.

Other filings. Across its 99 recent EDGAR filings, Cardinal Infrastructure Group Inc. most often filed 4 (24), SCHEDULE 13G (13), 3 (12), 8-K (11). A selection from 2026-08-14 to 2026-08-17:

The full record for CIK 2079999 is on the EDGAR company page; the latest 10-K there is dated 2026-03-23 and the oldest filing in the recent index dates from 2025-08-08. One example from this record is the 4 filed 2026-08-18 (document). Insider trades for Cardinal Infrastructure Group Inc. appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Carecloud, inc. bullish and bearish analyst opinions

For “Carecloud, inc. bullish and bearish analyst opinions”, the matching SEC registrant is CareCloud, Inc., which trades as CCLD and files under Central Index Key 1582982. EDGAR puts it in the “Services-Prepackaged Software” industry code with DE as its state or country of incorporation; its earlier registered name was MTBC, Inc. Data below comes straight from EDGAR as checked on Oct 25, 2026, where the latest item is a 3 filed 2026-10-05, across 1000 filings on record. This is reference material, not trading advice.

Business description, quoted from the 10-K filed 2026-03-12 by CareCloud, Inc. (CIK 1582982) — source document:

CareCloud, Inc., (together with its consolidated subsidiaries, “CareCloud,” the “Company,” “we,” “us” and/or “our”) is a leading provider of technology-enabled services and generative AI solutions that redefine the healthcare revenue cycle management process. We provide technology-enabled revenue cycle management and a full suite of proprietary cloud-based solutions to healthcare providers, from small practices to enterprise medical groups, hospitals, and health systems throughout the United States and certain other locations. Healthcare organizations today operate in highly complex and regulated environments. Our suite of technology-enabled solutions helps our clients increase financial and operational performance, streamline clinical workflows, and improve the patient experience.

Financial trend for CareCloud, Inc. from annual reports, periods 2022-12-31 to 2025-12-31: revenue went from $138.83 million (2022-12-31) to $120.50 million (2025-12-31), a change of -13.2%; net income (loss) went from $5.43 million (2022-12-31) to $10.80 million (2025-12-31), a change of +98.8%; total assets went from $136.17 million (2022-12-31) to $87.60 million (2025-12-31), a change of -35.7%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 1582982, tags Assets, NetIncomeLoss, RevenueFromContractWithCustomerExcludingAssessedTax; 4 periods shown, dashes mark figures CareCloud, Inc. did not tag for that period.

Analyst ratings, price targets and “bullish” or “bearish” calls on CareCloud, Inc. (CIK 1582982) are third-party opinions that the SEC does not publish or check. What the regulator does hold are the facts those views are built on: the latest results release filed under 8-K Item 2.02 is dated 2026-08-06, and the most recent 10-K annual report was filed 2026-03-12. Comparing any rating with those primary documents shows whether the thesis matches what the company itself reported.

Current reports. Of the 215 8-K or 6-K reports in CareCloud, Inc.’s recent EDGAR index, the 4 listed here run from 2026-06-05 to 2026-09-29, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 1582982 is on the EDGAR company page; the latest 10-K there is dated 2026-03-12 and the oldest filing in the recent index dates from 2014-05-02. Insider trades for CareCloud, Inc. appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Ccxi reddit

For “Ccxi reddit”, the matching SEC registrant is Churchill Capital Corp XI, which trades as CCXI, CCXIU, CCXIW and files under Central Index Key 2074973. EDGAR puts it in the “General Industrial Machinery & Equipment, NEC” industry code with Cayman Islands as its state or country of incorporation. Data below comes straight from EDGAR as checked on Oct 25, 2026, where the latest item is a 425 filed 2026-10-22, across 100 filings on record. This is reference material, not trading advice.

Business description, quoted from the 10-K filed 2026-03-26 by Churchill Capital Corp XI (CIK 2074973) — source document:

We are a blank check company incorporated on June 4, 2025 as a Cayman Islands exempted company and formed for the purpose of effecting a Business Combination with one or more businesses or entities. We may pursue an initial Business Combination in any business or industry. To date, our efforts have been limited to (i) organizational activities, (ii) activities related to our Initial Public Offering, and (iii) searching for and consummating a Business Combination. As of the date of this Report, we have not selected any specific Business Combination target. We have generated no operating revenues to date, and we do not expect that we will generate operating revenues until we consummate our initial Business Combination.

Financial trend for Churchill Capital Corp XI from quarterly and annual reports (three-month periods), periods 2026-03-31 to 2026-06-30: net income (loss) went from $3.17 million (2026-03-31) to -$134.68 million (2026-06-30), a change of -4346.8%; total assets went from $419.11 million (2026-03-31) to $422.64 million (2026-06-30), a change of +0.8%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 2074973, tags Assets, NetIncomeLoss; 2 periods shown, dashes mark figures Churchill Capital Corp XI did not tag for that period.

Reddit threads about Churchill Capital Corp XI, CIK 2074973, are user opinions, not disclosures. Claims made there can be checked against the filer record: 100 filings sit in its recent EDGAR index, the newest a 425 dated 2026-10-22, and 1 insider Form 4 reports are among them. The SEC’s Investor.gov site warns that social-media hype around small listed companies is a common feature of pump-and-dump schemes.

Current reports. Of the 10 8-K or 6-K reports in Churchill Capital Corp XI’s recent EDGAR index, the 4 listed here run from 2026-07-14 to 2026-10-13, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 2074973 is on the EDGAR company page; the latest 10-K there is dated 2026-03-26 and the oldest filing in the recent index dates from 2025-08-06. Insider trades for Churchill Capital Corp XI appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Centurion acquisition corp. bullish and bearish analyst opinions

For “Centurion acquisition corp. bullish and bearish analyst opinions”, the matching SEC registrant is Centurion Acquisition Corp., which trades as ALFUU, ALF, ALFUW and files under Central Index Key 2010930. EDGAR puts it in the “Blank Checks” industry code with Cayman Islands as its state or country of incorporation. Data below comes straight from EDGAR as checked on Oct 25, 2026, where the latest item is a SCHEDULE 13G/A filed 2026-09-04, across 90 filings on record. This is reference material, not trading advice.

Business description, quoted from the 10-K filed 2026-03-12 by Centurion Acquisition Corp. (CIK 2010930) — source document:

References in this Form 10-K to “we,” “us,” “our” or the “Company” refer to Centurion Acquisition Corp. References to our “management” or our “management team” refer to our officers and directors. Introduction We are a blank check company incorporated on January 18, 2024 as a Cayman Islands exempted company for the purpose of effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses (the “Business Combination”). We have 24 months from the closing of our initial public offering (“IPO” or “Initial Public Offering”), or until such earlier liquidation date as our board of directors may approve (the “Completion Window”) to complete our initial Business Combination.

Financial trend for Centurion Acquisition Corp. from annual reports, periods 2024-12-31 to 2025-12-31: net income (loss) was tagged only for 2025-12-31 at $11.74 million; total assets went from $296.66 million (2024-12-31) to $308.34 million (2025-12-31), a change of +3.9%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 2010930, tags Assets, NetIncomeLoss; 2 periods shown, dashes mark figures Centurion Acquisition Corp. did not tag for that period.

Analyst ratings, price targets and “bullish” or “bearish” calls on Centurion Acquisition Corp. (CIK 2010930) are third-party opinions that the SEC does not publish or check. What the regulator does hold are the facts those views are built on, and the most recent 10-K annual report was filed 2026-03-12. Comparing any rating with those primary documents shows whether the thesis matches what the company itself reported.

Deal and listing documents for Centurion Acquisition Corp. — registration statements, prospectuses and merger proxies — are filed on EDGAR; 3 such filings (424B4, S-1, S-1/A) appear in its recent index, the newest dated 2024-06-11.

Current reports. Of the 7 8-K or 6-K reports in Centurion Acquisition Corp.’s recent EDGAR index, the 4 listed here run from 2025-06-11 to 2026-06-16, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 2010930 is on the EDGAR company page; the latest 10-K there is dated 2026-03-12 and the oldest filing in the recent index dates from 2024-02-16. Insider trades for Centurion Acquisition Corp. appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Chung hwa chemical industrial works, ltd. bullish and bearish analyst opinions

The legal-form ending in “Chung hwa chemical industrial works, ltd.” is the clue: “Limited” is the company form used across Hong Kong, Australia, Singapore and other Commonwealth markets. A company of that kind reports in a Commonwealth jurisdiction (most often Hong Kong, Australia, Singapore or Canada), so the place to read its annual report and announcements is that market’s exchange filing system (HKEXnews, ASX announcements, SGXNet or SEDAR+) — www.hkexnews.hk.

No SEC filer could be matched to “Chung hwa chemical industrial works, ltd. bullish and bearish analyst opinions” with a single, clear Central Index Key: the phrase “Chung hwa chemical industrial works, ltd.” appears in 911+ EDGAR full-text search results, but those hits do not point to one clearly identifiable issuer with its own CIK. Rather than show another company’s numbers, this section explains what the official record does and does not contain for the term “chung” (search terms considered: chung, hwa, chemical, industrial, works).

A broader EDGAR full-text search for the shorter phrase “Chung hwa chemical” finds 911+ filing documents; among the top 100, the filers mentioning it most are DIMENSIONAL EMERGING MARKETS VALUE FUND (CIK 0000896163) (28); AMERICAN CENTURY ETF TRUST (CIK 0001710607) (27); Dimensional ETF Trust (CIK 0001816125) (24). Those are documents that name the term, not proof that any of these filers is the business in the search.

In the 100 most relevant full-text hits returned for “Chung hwa chemical industrial works, ltd.”, filings range from 2021-12-09 to 2026-09-24. The filers whose documents mention it most often are DIMENSIONAL EMERGING MARKETS VALUE FUND (CIK 0000896163) (28 hits); AMERICAN CENTURY ETF TRUST (CIK 0001710607) (27 hits); Dimensional ETF Trust (CIK 0001816125) (24 hits); DFA INVESTMENT DIMENSIONS GROUP INC (CIK 0000355437) (18 hits). A mention in another company’s filing — as a customer, supplier, lender, fund holding or deal counterparty — does not make that filer the company you searched for.

EDGAR’s company index has 190 entities whose registered name contains the word “chung”; the first few are shown below so you can see whether any is the business you mean. None of them matches the full search wording closely enough to be treated as the same company.

Word by word, the number of EDGAR registrant names containing each term of this search is: “chung” 190, “hwa” 24, “chemical” 227, “industrial” 491, “works” 220. A term that appears in many unrelated names is a weak identifier on its own, which is why this page does not attach any one filer’s financial data to the query.

For this particular search: analyst views on “chung” are third-party opinions; the SEC neither issues nor reviews ratings, so check any rating against the company’s own annual report. If the business says it is registered but does not appear in EDGAR or on FINRA BrokerCheck, treat that as a red flag. This page offers no buy or sell recommendation.

Updated Oct 25, 2026 ET

Cisco unity connection cve 2026

“Cisco unity connection cve 2026” is a software-security lookup: CVE identifiers are assigned under the MITRE CVE program and scored in the U.S. National Vulnerability Database, and the vendor’s own advisories list the fixed releases. Search the NVD for this product and check the vendor security advisory page, because SEC filings only mention vulnerabilities in aggregate.

No SEC filer could be matched to “Cisco unity connection cve 2026” with a single, clear Central Index Key: the phrase “Cisco unity connection” appears in 1 EDGAR full-text search results, but those hits do not point to one clearly identifiable issuer with its own CIK. Rather than show another company’s numbers, this section explains what the official record does and does not contain for the term “cisco” (search terms considered: cisco, unity, connection).

Vulnerability records for Cisco Unity Connection. Security flaws are catalogued by the U.S. National Vulnerability Database (NVD), run by NIST, not by the SEC. A keyword query of the NVD on Oct 25, 2026 returned 69 CVE entries whose descriptions mention Cisco Unity Connection; 16 of them were published in 2026, the newest being CVE-2026-76481 on 2026-10-21. Severity scores below are the CVSS base scores NVD lists; vendor advisories give fixed versions.

In the 1 most relevant full-text hits returned for “Cisco unity connection”, filings range from 2015-03-02 to 2015-03-02. The filers whose documents mention it most often are HEALTH NET INC (CIK 0000916085) (1 hit). A mention in another company’s filing — as a customer, supplier, lender, fund holding or deal counterparty — does not make that filer the company you searched for.

Word by word, the number of EDGAR registrant names containing each term of this search is: “cisco” 8, “unity” 171, “connection” 53. A term that appears in many unrelated names is a weak identifier on its own, which is why this page does not attach any one filer’s financial data to the query.

Updated Oct 25, 2026 ET

Citigroup capital xiii tr pfd secs bullish and bearish analyst opinions

For “Citigroup capital xiii tr pfd secs bullish and bearish analyst opinions”, the matching SEC registrant is CITIGROUP INC, which trades as C, C-PN, C-PR and files under Central Index Key 831001. EDGAR puts it in the “National Commercial Banks” industry code with DE as its state or country of incorporation; its earlier registered name was CITIGROUP INC. Data below comes straight from EDGAR as checked on Oct 25, 2026, where the latest item is a 424B3 filed 2026-10-23 (this view begins at filings dated on or before 2026-10-23), across 13147 filings on record. This is reference material, not trading advice.

Financial trend for CITIGROUP INC from quarterly and annual reports (three-month periods), periods 2025-03-31 to 2025-09-30: revenue went from $21.60 billion (2025-03-31) to $22.09 billion (2025-09-30), a change of +2.3%; net income (loss) went from $4.06 billion (2025-03-31) to $3.75 billion (2025-09-30), a change of -7.7%; total assets went from $2,571.51 billion (2025-03-31) to $2,642.47 billion (2025-09-30), a change of +2.8%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 831001, tags Assets, NetIncomeLoss, Revenues; 3 periods shown, dashes mark figures CITIGROUP INC did not tag for that period.

Current reports. Of the 15 8-K or 6-K reports in CITIGROUP INC’s recent EDGAR index, the 4 listed here run from 2026-02-12 to 2026-05-21, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 831001 is on the EDGAR company page; the latest 10-K there is dated 2026-02-20 and the oldest filing in the recent index dates from 2025-10-24. One example from this record is the 3 filed 2026-10-23 (document). Insider trades for CITIGROUP INC appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Clinuvel

What this search refers to. Clinuvel Pharmaceuticals is an Australian biopharmaceutical company (maker of Scenesse/afamelanotide) listed on the ASX; it publishes its reports through ASX announcements rather than EDGAR. Official source: www.asx.com.au.

No SEC filer could be matched to “Clinuvel” with a single, clear Central Index Key: the phrase “Clinuvel” appears in 7265+ EDGAR full-text search results, but those hits do not point to one clearly identifiable issuer with its own CIK. Rather than show another company’s numbers, this section explains what the official record does and does not contain for the term “clinuvel” (search terms considered: clinuvel).

In the 100 most relevant full-text hits returned for “Clinuvel”, filings range from 2006-03-10 to 2026-10-22. The filers whose documents mention it most often are Clinuvel Pharmaceuticals Ltd (CUVL, CLVLF) (CIK 0001290877) (27 hits); Clinuvel Pharmaceuticals Ltd (CIK 0001290877) (18 hits); Clinuvel Pharmaceuticals Ltd (CUVL, CLVLF, CLVLY) (CIK 0001290877) (13 hits); COMPETITIVE TECHNOLOGIES INC (CIK 0000102198) (13 hits). A mention in another company’s filing — as a customer, supplier, lender, fund holding or deal counterparty — does not make that filer the company you searched for.

EDGAR’s company index has 1 entities whose registered name contains the word “clinuvel”; the first few are shown below so you can see whether any is the business you mean. None of them matches the full search wording closely enough to be treated as the same company.

Word by word, the number of EDGAR registrant names containing each term of this search is: “clinuvel” 1. A term that appears in many unrelated names is a weak identifier on its own, which is why this page does not attach any one filer’s financial data to the query.

Sample EDGAR registrant names, term by term — containing “clinuvel”: CLINUVEL PHARMACEUTICALS LTD (CIK 1290877). These are listed only to show how the individual words map onto unrelated filers; none should be read as the subject of the search.

For this particular search: if “clinuvel” is a brand or product, the listed parent may file under a different name, so search the parent’s legal name in EDGAR company search. If the business says it is registered but does not appear in EDGAR or on FINRA BrokerCheck, treat that as a red flag. This page offers no buy or sell recommendation.

Updated Oct 25, 2026 ET

Community health systems cyh latest news

For “Community health systems cyh latest news”, the matching SEC registrant is COMMUNITY HEALTH SYSTEMS INC, which trades as CYH and files under Central Index Key 1108109. EDGAR puts it in the “Services-General Medical & Surgical Hospitals, NEC” industry code with DE as its state or country of incorporation; its earlier registered name was COMMUNITY HEALTH SYSTEMS INC/. Data below comes straight from EDGAR as checked on Oct 25, 2026, where the latest item is a 4 filed 2026-08-25, across 1000 filings on record. This is reference material, not trading advice.

Business description, quoted from the 10-K filed 2026-02-19 by COMMUNITY HEALTH SYSTEMS INC (CIK 1108109) — source document:

We are one of the nation’s largest healthcare companies. Our affiliates are leading providers of healthcare services, developing and operating healthcare delivery systems in 36 distinct markets across 14 states. At December 31, 2025, our subsidiaries own or lease 69 affiliated hospitals, with more than 10,000 beds, and operate more than 1,000 sites of care, including physician practices, urgent care centers, freestanding emergency departments, occupational medicine clinics, imaging centers, cancer centers and ambulatory surgery centers. We generate revenues by providing a broad range of general and specialized hospital healthcare services and outpatient services to patients in the communities in which we are located. For the hospitals and other sites of care that we own and operate, we are paid for our services by governmental agencies, private insurers and directly by the patients we serve.

Financial trend for COMMUNITY HEALTH SYSTEMS INC from annual reports, periods 2022-12-31 to 2025-12-31: revenue went from $12.21 billion (2022-12-31) to $12.48 billion (2025-12-31), a change of +2.2%; net income (loss) went from $46.00 million (2022-12-31) to $509.00 million (2025-12-31), a change of +1006.5%; total assets went from $14.67 billion (2022-12-31) to $13.20 billion (2025-12-31), a change of -10.0%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 1108109, tags Assets, NetIncomeLoss, Revenues; 4 periods shown, dashes mark figures COMMUNITY HEALTH SYSTEMS INC did not tag for that period.

For the latest news, the fastest official source is the filing feed: COMMUNITY HEALTH SYSTEMS INC (CIK 1108109) filed 242 current reports (8-K or 6-K) in its recent EDGAR window, the newest on 2026-07-22, and its overall latest filing is a 4 dated 2026-08-25. Companies must file an 8-K within four business days of most material events.

Current reports. Of the 242 8-K or 6-K reports in COMMUNITY HEALTH SYSTEMS INC’s recent EDGAR index, the 4 listed here run from 2026-05-06 to 2026-07-22, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 1108109 is on the EDGAR company page; the latest 10-K there is dated 2026-02-19 and the oldest filing in the recent index dates from 2014-01-27. Insider trades for COMMUNITY HEALTH SYSTEMS INC appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Community health systems cyh news october 2026

For “Community health systems cyh news october 2026”, the matching SEC registrant is COMMUNITY HEALTH SYSTEMS INC, which trades as CYH and files under Central Index Key 1108109. EDGAR puts it in the “Services-General Medical & Surgical Hospitals, NEC” industry code with DE as its state or country of incorporation; its earlier registered name was COMMUNITY HEALTH SYSTEMS INC/. Data below comes straight from EDGAR as checked on Oct 25, 2026, where the latest item is a 4 filed 2026-08-25 (this view begins at filings dated on or before 2026-05-14), across 1000 filings on record. This is reference material, not trading advice.

Business description, quoted from the 10-K filed 2026-02-19 by COMMUNITY HEALTH SYSTEMS INC (CIK 1108109) (passage 2, continuing from the earlier excerpt) — source document:

Services provided through our hospitals and outpatient facilities include general acute care, emergency room, general and specialty surgery, critical care, internal medicine, obstetrics, diagnostic, psychiatric and rehabilitation services. An integral part of providing these services is our network of affiliated physicians at our hospitals and affiliated businesses. At December 31, 2025, we employed approximately 1,700 physicians and an additional 1,400 licensed healthcare practitioners. Through our management and operation of these businesses, we provide standardization and centralization of operations across key business areas; strategic assistance to expand and improve services and facilities; implementation of patient safety and quality of care improvement programs and assistance in the recruitment of additional physicians and licensed healthcare practitioners to the markets in which our hospitals are located.

Financial trend for COMMUNITY HEALTH SYSTEMS INC from quarterly and annual reports (three-month periods), periods 2025-09-30 to 2026-06-30: revenue went from $3.09 billion (2025-09-30) to $2.83 billion (2026-06-30), a change of -8.5%; net income (loss) went from $130.00 million (2025-09-30) to $70.00 million (2026-06-30), a change of -46.2%; total assets went from $13.24 billion (2025-09-30) to $12.18 billion (2026-06-30), a change of -8.0%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 1108109, tags Assets, NetIncomeLoss, Revenues; 3 periods shown, dashes mark figures COMMUNITY HEALTH SYSTEMS INC did not tag for that period.

Current reports. Of the 242 8-K or 6-K reports in COMMUNITY HEALTH SYSTEMS INC’s recent EDGAR index, the 4 listed here run from 2026-03-05 to 2026-04-23, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 1108109 is on the EDGAR company page; the latest 10-K there is dated 2026-02-19 and the oldest filing in the recent index dates from 2014-01-27. One example from this record is the 8-K filed 2026-07-22 (document). Insider trades for COMMUNITY HEALTH SYSTEMS INC appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Crexendo, inc. bullish and bearish analyst opinions

For “Crexendo, inc. bullish and bearish analyst opinions”, the matching SEC registrant is Crexendo, Inc., which trades as CXDO and files under Central Index Key 1075736. EDGAR puts it in the “Telephone Communications (No Radiotelephone)” industry code with DE as its state or country of incorporation; its earlier registered name was IMERGENT INC. Data below comes straight from EDGAR as checked on Oct 25, 2026, where the latest item is a DEF 14A filed 2026-10-19, across 1000 filings on record. This is reference material, not trading advice.

Business description, quoted from the 10-K filed 2026-03-03 by Crexendo, Inc. (CIK 1075736) — source document:

Crexendo, Inc. is an award-winning software technology company that is a premier provider of cloud communication platform software and unified communications as a service (UCaaS) offering, including voice, video, contact center, and managed IT services tailored to businesses of all sizes. Our cloud communications software solutions currently support over seven million end users globally, through an extensive network of over 240 cloud communication platform software subscribers and our direct retail offering. Our products and services can be categorized in the following offerings: Cloud Telecommunications Services – Our cloud telecommunications services transmit calls using IP or cloud technology, which converts voice signals into digital data packets for transmission over the Internet or cloud.

Financial trend for Crexendo, Inc. from annual reports, periods 2022-12-31 to 2025-12-31: revenue went from $37.55 million (2022-12-31) to $68.17 million (2025-12-31), a change of +81.5%; net income (loss) went from -$35.41 million (2022-12-31) to $5.07 million (2025-12-31), a change of +114.3%; total assets went from $55.63 million (2022-12-31) to $77.69 million (2025-12-31), a change of +39.6%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 1075736, tags Assets, NetIncomeLoss, Revenues; 4 periods shown, dashes mark figures Crexendo, Inc. did not tag for that period.

Analyst ratings, price targets and “bullish” or “bearish” calls on Crexendo, Inc. (CIK 1075736) are third-party opinions that the SEC does not publish or check. What the regulator does hold are the facts those views are built on: the latest results release filed under 8-K Item 2.02 is dated 2026-08-04, and the most recent 10-K annual report was filed 2026-03-03. Comparing any rating with those primary documents shows whether the thesis matches what the company itself reported.

Current reports. Of the 113 8-K or 6-K reports in Crexendo, Inc.’s recent EDGAR index, the 4 listed here run from 2026-07-30 to 2026-10-13, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 1075736 is on the EDGAR company page; the latest 10-K there is dated 2026-03-03 and the oldest filing in the recent index dates from 2016-11-03. Insider trades for Crexendo, Inc. appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Daio paper corporation bullish and bearish analyst opinions

What this search refers to. Daio Paper Corporation is a Japanese paper and tissue maker listed on the Tokyo Stock Exchange; Japanese issuers file securities reports on EDINET. Official source: disclosure2.edinet-fsa.go.jp.

No SEC filer could be matched to “Daio paper corporation bullish and bearish analyst opinions” with a single, clear Central Index Key: the phrase “Daio paper corporation” appears in 1068+ EDGAR full-text search results, but those hits do not point to one clearly identifiable issuer with its own CIK. Rather than show another company’s numbers, this section explains what the official record does and does not contain for the term “daio” (search terms considered: daio, paper, corporation).

In the 100 most relevant full-text hits returned for “Daio paper corporation”, filings range from 2005-01-21 to 2026-10-23. The filers whose documents mention it most often are MUTUAL FUND SERIES TRUST (CIK 0001355064) (57 hits); Dimensional ETF Trust (CIK 0001816125) (15 hits); JNL SERIES TRUST (CIK 0000933691) (7 hits); JAPAN SMALLER CAPITALIZATION FUND INC (JOF) (CIK 0000859796) (4 hits). A mention in another company’s filing — as a customer, supplier, lender, fund holding or deal counterparty — does not make that filer the company you searched for.

EDGAR’s company index has 0 entities whose registered name contains the word “daio”, so the business is most likely not registered with the SEC under that name.

Word by word, the number of EDGAR registrant names containing each term of this search is: “daio” 0, “paper” 158, “corporation” 486. A term that appears in many unrelated names is a weak identifier on its own, which is why this page does not attach any one filer’s financial data to the query.

Sample EDGAR registrant names, term by term — containing “paper”: ACR GROUP PAPER HOLDINGS JR GP LLC (CIK 1979482), ACR GROUP PAPER HOLDINGS JR LP (CIK 1980027), ACR GROUP PAPER HOLDINGS LP (CIK 1923083); containing “corporation”: 1787 FINANCIAL CORPORATION, INC. (CIK 1706256), A.BRIDGE REALVEST SECURITIES CORPORATION (CIK 1005399), ABACUS SECURITIES CORPORATION (CIK 783252). These are listed only to show how the individual words map onto unrelated filers; none should be read as the subject of the search.

For this particular search: analyst views on “daio” are third-party opinions; the SEC neither issues nor reviews ratings, so check any rating against the company’s own annual report. If the business says it is registered but does not appear in EDGAR or on FINRA BrokerCheck, treat that as a red flag. This page offers no buy or sell recommendation.

Updated Oct 25, 2026 ET

Ellington financial efc latest news october 2026

For “Ellington financial efc latest news october 2026”, the matching SEC registrant is Ellington Financial Inc., which trades as EFC, EFC-PB, EFC-PC, EFC-PD and files under Central Index Key 1411342. EDGAR puts it in the “Real Estate” industry code with DE as its state or country of incorporation; its earlier registered name was Ellington Financial LLC. Data below comes straight from EDGAR as checked on Oct 25, 2026, where the latest item is a 8-K filed 2026-10-07, across 1002 filings on record. This is reference material, not trading advice.

Business description, quoted from the 10-K filed 2026-03-02 by Ellington Financial Inc. (CIK 1411342) — source document:

Except where the context suggests otherwise, references in this Annual Report on Form 10-K to "EFC," "we," "us," and "our" refer to Ellington Financial Inc. and its consolidated subsidiaries, including Ellington Financial Operating Partnership LLC, our operating partnership subsidiary, which we refer to as our "Operating Partnership." References in this Annual Report on Form 10-K to (1) "common shares" refer to shares of our common stock, $0.001 par value per share and (2) "common stockholders" refer to holders of shares of our common stock. We conduct all of our operations and business activities through our Operating Partnership. Our "Manager" refers to Ellington Financial Management LLC, our external manager, "Ellington" refers to Ellington Management Group, L.L.C. and its affiliated investment advisory firms, including our Manager, and "Manager Group" refers collectively to officers and directors of EFC, and partners and affiliates of Ellington (including families and family trusts of the foregoing).

Financial trend for Ellington Financial Inc. from annual reports, periods 2022-12-31 to 2025-12-31: net income (loss) went from -$85.34 million (2022-12-31) to $118.74 million (2025-12-31), a change of +239.1%; total assets went from $14.09 billion (2022-12-31) to $19.35 billion (2025-12-31), a change of +37.4%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 1411342, tags Assets, NetIncomeLoss; 4 periods shown, dashes mark figures Ellington Financial Inc. did not tag for that period.

For reported results, Ellington Financial Inc.’s (CIK 1411342) latest 10-Q is dated 2026-08-10 and its latest annual report (10-K) 2026-03-02. Earnings releases appear as 8-K Item 2.02 filings; 69 are in the recent index, the newest on 2026-08-07.

For the latest news, the fastest official source is the filing feed: Ellington Financial Inc. (CIK 1411342) filed 513 current reports (8-K or 6-K) in its recent EDGAR window, the newest on 2026-10-07, and its overall latest filing is a 8-K dated 2026-10-07. Companies must file an 8-K within four business days of most material events.

Current reports. Of the 513 8-K or 6-K reports in Ellington Financial Inc.’s recent EDGAR index, the 4 listed here run from 2026-09-14 to 2026-10-07, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 1411342 is on the EDGAR company page; the latest 10-K there is dated 2026-03-02 and the oldest filing in the recent index dates from 2010-10-07. Insider trades for Ellington Financial Inc. appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Ellkay latest news product partnership healthcare data

What this search refers to. Ellkay is a privately held U.S. healthcare-data interoperability company; product and partnership news comes from its own press releases, since a private firm files no 8-K reports. Corporate-registry check: OpenCorporates search for “Ellkay latest news product partnership healthcare data”.

No SEC filer could be matched to “Ellkay latest news product partnership healthcare data” with a single, clear Central Index Key: neither EDGAR’s company index nor its full-text search (phrase “Ellkay product partnership healthcare data”) returns a registrant with this name. Rather than show another company’s numbers, this section explains what the official record does and does not contain for the term “ellkay” (search terms considered: ellkay, product, partnership, healthcare, data).

Even the shorter phrase “Ellkay product partnership” returns no EDGAR full-text hits, so no SEC filing since 2001 mentions it; the terms in this search (ellkay, product, partnership, healthcare, data) point to a business outside the SEC system or one known by another legal name.

EDGAR’s company index has 0 entities whose registered name contains the word “ellkay”, so the business is most likely not registered with the SEC under that name.

Word by word, the number of EDGAR registrant names containing each term of this search is: “ellkay” 0, “product” 84, “partnership” 490, “healthcare” 466, “data” 483. A term that appears in many unrelated names is a weak identifier on its own, which is why this page does not attach any one filer’s financial data to the query.

Sample EDGAR registrant names, term by term — containing “product”: 3D PRODUCT IMAGING, INC. (CIK 1597311), AAL VARIABLE PRODUCT SERIES FUND INC (CIK 927648), AMERICAN PRODUCT CORP (CIK 1114098); containing “partnership”: 1019 FIFTH STREET LIMITED PARTNERSHIP (CIK 1647876), 110 YARDS LIMITED PARTNERSHIP (CIK 2094593), 115 HUTCHINSON INVESTMENT LIMITED PARTNERSHIP (CIK 2050533); containing “healthcare”: 1 NORTH EQUITY HEALTHCARE LONG/SHORT FUND LLC (CIK 1591835), 1LIFE HEALTHCARE INC (CIK 1404123), 21ST CENTURY HEALTHCARE INC (CIK 1041939); containing “data”: 15 DATA LINK/MALAYSIA, LLC (CIK 1705845), 1547 DATA CENTER FUND III, L.P. (CIK 2028057), 1547 DATA CENTER REAL ESTATE FUND II, L.P. (CIK 1821445). These are listed only to show how the individual words map onto unrelated filers; none should be read as the subject of the search.

For this particular search: for recent news on “ellkay”, use the company’s own press releases or its home-exchange announcements, since there is no SEC 8-K feed for a non-filer. If the business says it is registered but does not appear in EDGAR or on FINRA BrokerCheck, treat that as a red flag. This page offers no buy or sell recommendation.

Updated Oct 25, 2026 ET

Enova international enva latest news october 2026

For “Enova international enva latest news october 2026”, the matching SEC registrant is Enova International, Inc., which trades as ENVA and files under Central Index Key 1529864. EDGAR puts it in the “Personal Credit Institutions” industry code with DE as its state or country of incorporation; its earlier registered name was Enova International, Inc. Data below comes straight from EDGAR as checked on Oct 25, 2026, where the latest item is a POS AM filed 2026-10-23, across 1000 filings on record. This is reference material, not trading advice.

Financial trend for Enova International, Inc. from annual reports, periods 2022-12-31 to 2025-12-31: revenue went from $1.74 billion (2022-12-31) to $3.15 billion (2025-12-31), a change of +81.5%; net income (loss) went from $207.42 million (2022-12-31) to $308.39 million (2025-12-31), a change of +48.7%; total assets went from $3.78 billion (2022-12-31) to $6.47 billion (2025-12-31), a change of +71.1%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 1529864, tags Assets, NetIncomeLoss, Revenues; 4 periods shown, dashes mark figures Enova International, Inc. did not tag for that period.

For the latest news, the fastest official source is the filing feed: Enova International, Inc. (CIK 1529864) filed 170 current reports (8-K or 6-K) in its recent EDGAR window, the newest on 2026-10-22, and its overall latest filing is a POS AM dated 2026-10-23. Companies must file an 8-K within four business days of most material events.

Current reports. Of the 170 8-K or 6-K reports in Enova International, Inc.’s recent EDGAR index, the 4 listed here run from 2026-09-25 to 2026-10-22, with the item codes the company selected and what each code covers under SEC rules.

Other filings. Across its 1000 recent EDGAR filings, Enova International, Inc. most often filed 4 (505), 8-K (170), 144 (109), 10-Q (32). A selection from 2026-08-27 to 2026-10-23:

The full record for CIK 1529864 is on the EDGAR company page; the latest 10-K there is dated 2026-02-20 and the oldest filing in the recent index dates from 2016-05-23. Insider trades for Enova International, Inc. appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Enpro inc npo latest news

For “Enpro inc npo latest news”, the matching SEC registrant is Enpro Inc., which trades as NPO and files under Central Index Key 1164863. EDGAR puts it in the “Gaskets, Packg & Sealg Devices & Rubber & Plastics Hose” industry code with NC as its state or country of incorporation; its earlier registered name was ENPRO INDUSTRIES, INC. Data below comes straight from EDGAR as checked on Oct 25, 2026, where the latest item is a 4 filed 2026-10-01, across 1000 filings on record. This is reference material, not trading advice.

Updated Oct 25, 2026 ET

Ernexa therapeutics inc. bullish and bearish analyst opinions

For “Ernexa therapeutics inc. bullish and bearish analyst opinions”, the matching SEC registrant is Ernexa Therapeutics Inc., which trades as ERNA, ERNAW and files under Central Index Key 748592. EDGAR puts it in the “Pharmaceutical Preparations” industry code with DE as its state or country of incorporation; its earlier registered name was Eterna Therapeutics Inc. Data below comes straight from EDGAR as checked on Oct 25, 2026, where the latest item is a 8-K filed 2026-10-15, across 1002 filings on record. This is reference material, not trading advice.

Business description, quoted from the 10-K filed 2026-03-13 by Ernexa Therapeutics Inc. (CIK 748592) — source document:

We are a preclinical-stage synthetic allogeneic iMSC therapy company. iMSCs are induced pluripotent stem cell (“iPSC”)-derived mesenchymal stem cells. We envision a future where cell therapies powered by synthetic iMSCs can offer new options for patients with limited treatment paths and our mission is to transform the treatment of cancer and autoimmune disease by developing scalable, affordable, off-the-shelf cell therapies that restore hope. Objectives and Business Strategy Our lead product candidate ERNA-101 is allogenic IL-7 and IL-15-secreting iMSCs. ERNA-101 capitalizes on the intrinsic tumor-homing ability of MSCs to slip through the tumor’s defenses and to deliver potent pro-inflammatory factors directly to the tumor microenvironment (“TME”), limiting systemic exposure and potential toxicity while potentially unleashing potent anti-cancer immune responses including enhancement of T-cell anti-tumor activity.

Financial trend for Ernexa Therapeutics Inc. from annual reports, periods 2022-12-31 to 2025-12-31: revenue went from $0 (2022-12-31) to $582,000 (2024-12-31); net income (loss) went from -$24.58 million (2022-12-31) to -$14.08 million (2025-12-31), a change of +42.7%; total assets went from $22.28 million (2022-12-31) to $5.83 million (2025-12-31), a change of -73.8%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 748592, tags Assets, NetIncomeLoss, Revenues; 4 periods shown, dashes mark figures Ernexa Therapeutics Inc. did not tag for that period.

Analyst ratings, price targets and “bullish” or “bearish” calls on Ernexa Therapeutics Inc. (CIK 748592) are third-party opinions that the SEC does not publish or check. What the regulator does hold are the facts those views are built on: the latest results release filed under 8-K Item 2.02 is dated 2023-03-20, and the most recent 10-K annual report was filed 2026-03-13. Comparing any rating with those primary documents shows whether the thesis matches what the company itself reported.

Current reports. Of the 248 8-K or 6-K reports in Ernexa Therapeutics Inc.’s recent EDGAR index, the 4 listed here run from 2026-07-02 to 2026-10-15, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 748592 is on the EDGAR company page; the latest 10-K there is dated 2026-03-13 and the oldest filing in the recent index dates from 2010-06-02. Insider trades for Ernexa Therapeutics Inc. appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Evlv stock news

For “Evlv stock news”, the matching SEC registrant is Evolv Technologies Holdings, Inc., which trades as EVLV and files under Central Index Key 1805385. EDGAR puts it in the “Computer Peripheral Equipment, NEC” industry code with an unstated jurisdiction as its state or country of incorporation; its earlier registered name was NewHold Investment Corp. Data below comes straight from EDGAR as checked on Oct 25, 2026, where the latest item is a 4 filed 2026-10-06, across 549 filings on record. This is reference material, not trading advice.

Business description, quoted from the 10-K filed 2026-03-10 by Evolv Technologies Holdings, Inc. (CIK 1805385) — source document:

Evolv Technologies Holdings, Inc., a Delaware corporation formed in 2021 (“we,” “us,” “our,” the “Company” and “Evolv”) is a leading security technology company pioneering Artificial Intelligence (“AI”)-powered screening solutions designed to help create safer environments while maintaining efficient visitor flow and a positive visitor experience. We serve customers across a range of end markets, including education, healthcare, sports, live entertainment, tourist attractions, houses of worship, and industrial workplaces. Our mission is to make the world a safer and more enjoyable place to live, work, learn, and play. Our goal is to help facility operators address escalating gun violence, mass shootings and terrorist attacks while maintaining a positive visitor experience. Our solutions are delivered through a Security-as-a-Service model that integrates our proprietary sensor platform and AI-powered software, cloud connectivity, and ongoing services.

Financial trend for Evolv Technologies Holdings, Inc. from annual reports, periods 2024-03-31 to 2025-12-31: revenue went from $103.86 million (2024-12-31) to $145.91 million (2025-12-31), a change of +40.5%; net income (loss) went from -$54.02 million (2024-12-31) to -$33.14 million (2025-12-31), a change of +38.7%; total assets went from $280.00 million (2024-03-31) to $304.41 million (2025-12-31), a change of +8.7%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 1805385, tags Assets, NetIncomeLoss, Revenues; 4 periods shown, dashes mark figures Evolv Technologies Holdings, Inc. did not tag for that period.

For the latest news, the fastest official source is the filing feed: Evolv Technologies Holdings, Inc. (CIK 1805385) filed 72 current reports (8-K or 6-K) in its recent EDGAR window, the newest on 2026-08-11, and its overall latest filing is a 4 dated 2026-10-06. Companies must file an 8-K within four business days of most material events.

Current reports. Of the 72 8-K or 6-K reports in Evolv Technologies Holdings, Inc.’s recent EDGAR index, the 4 listed here run from 2026-05-13 to 2026-08-11, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 1805385 is on the EDGAR company page; the latest 10-K there is dated 2026-03-10 and the oldest filing in the recent index dates from 2020-03-10. Insider trades for Evolv Technologies Holdings, Inc. appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

First busey corporation bullish and bearish analyst opinions

For “First busey corporation bullish and bearish analyst opinions”, the matching SEC registrant is FIRST BUSEY CORP /NV/, which trades as BUSE, BUSEP and files under Central Index Key 314489. EDGAR puts it in the “State Commercial Banks” industry code with NV as its state or country of incorporation. Data below comes straight from EDGAR as checked on Oct 25, 2026, where the latest item is a 4 filed 2026-10-16, across 1001 filings on record. This is reference material, not trading advice.

Business description, quoted from the 10-K filed 2026-02-26 by FIRST BUSEY CORP /NV/ (CIK 314489) — source document:

Organized in Nevada in 1980, First Busey Corporation is headquartered in Leawood, Kansas. First Busey Corporation’s common stock is traded on The Nasdaq Global Select Market under the symbol “BUSE” and its Series B preferred stock is traded on The Nasdaq Global Select Market under the symbol “BUSEP.” Busey conducts the business of banking and provides related banking services, asset management, brokerage, and fiduciary services through Busey Bank, and provides payment technology solutions through FirsTech. Busey also has various other subsidiaries that are not significant to the consolidated entity. Banking Busey Bank is an Illinois state-chartered bank headquartered in Champaign, Illinois. Initially founded in 1868, Busey Bank now has a total of 79 banking centers across 10 states, with 50 in Illinois, nine in Missouri, four in Texas, three in Colorado, three in Florida, three in Kansas, three in Oklahoma, two in Arizona, one in Indiana, and one in New Mexico.

Financial trend for FIRST BUSEY CORP /NV/ from annual reports, periods 2022-12-31 to 2025-12-31: revenue went from $450.24 million (2022-12-31) to $719.58 million (2025-12-31), a change of +59.8%; net income (loss) went from $128.31 million (2022-12-31) to $135.26 million (2025-12-31), a change of +5.4%; total assets went from $12.34 billion (2022-12-31) to $18.10 billion (2025-12-31), a change of +46.8%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 314489, tags Assets, NetIncomeLoss, Revenues; 4 periods shown, dashes mark figures FIRST BUSEY CORP /NV/ did not tag for that period.

Analyst ratings, price targets and “bullish” or “bearish” calls on FIRST BUSEY CORP /NV/ (CIK 314489) are third-party opinions that the SEC does not publish or check. What the regulator does hold are the facts those views are built on: the latest results release filed under 8-K Item 2.02 is dated 2026-07-28, and the most recent 10-K annual report was filed 2026-02-26. Comparing any rating with those primary documents shows whether the thesis matches what the company itself reported.

Current reports. Of the 100 8-K or 6-K reports in FIRST BUSEY CORP /NV/’s recent EDGAR index, the 4 listed here run from 2026-07-28 to 2026-10-13, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 314489 is on the EDGAR company page; the latest 10-K there is dated 2026-02-26 and the oldest filing in the recent index dates from 2020-05-04. Insider trades for FIRST BUSEY CORP /NV/ appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Globavend holdings limited bullish and bearish analyst opinions

For “Globavend holdings limited bullish and bearish analyst opinions”, the matching SEC registrant is Globavend Holdings Ltd, which trades as GVH and files under Central Index Key 1978527. EDGAR puts it in the “Arrangement of Transportation of Freight & Cargo” industry code with Cayman Islands as its state or country of incorporation. Data below comes straight from EDGAR as checked on Oct 25, 2026, where the latest item is a SCHEDULE 13G/A filed 2026-08-13, across 107 filings on record. This is reference material, not trading advice.

Analyst ratings, price targets and “bullish” or “bearish” calls on Globavend Holdings Ltd (CIK 1978527) are third-party opinions that the SEC does not publish or check. What the regulator does hold are the facts those views are built on, and the most recent 20-F annual report was filed 2026-02-13. Comparing any rating with those primary documents shows whether the thesis matches what the company itself reported.

Updated Oct 25, 2026 ET

Grifols, s.a. bullish and bearish analyst opinions

For “Grifols, s.a. bullish and bearish analyst opinions”, the matching SEC registrant is Grifols SA, which trades as GRFS, GIFLF, GIFOF, GIKLY and files under Central Index Key 1438569. EDGAR puts it in the “Pharmaceutical Preparations” industry code with an unstated jurisdiction as its state or country of incorporation. Data below comes straight from EDGAR as checked on Oct 25, 2026, where the latest item is a 6-K filed 2026-07-30, across 461 filings on record. This is reference material, not trading advice.

Business description, quoted from the 20-F filed 2026-04-17 by Grifols SA (CIK 1438569) — source document:

OPERATING AND FINANCIAL REVIEW AND PROSPECTS 95 A. Operating Results 96 B. Liquidity and Capital Resources 109 C. Research and Development, Patents and Licenses 128 D. Trend Information 128 E. Critical Accounting Estimates 129 Item 6. DIRECTORS, SENIOR MANAGEMENT AND EMPLOYEES 129 A. Directors and Senior Management 129 B. Compensation 138 C. Board Practices 143 D. Employees 149 E. Share Ownership 150 F. Disclosure of a Registrant’s Action to Recover Erroneously Awarded Compensation. 151 Item 7. MAJOR SHAREHOLDERS AND RELATED PARTY TRANSACTIONS 151 A. Major Shareholders 151 B. Related Party Transactions 153 C. Interests of Experts and Counsel 157 Item 8. FINANCIAL INFORMATION 157 A. Consolidated Statements and Other Financial Information 157 B. Significant Changes 159 Item 9.

Financial trend for Grifols SA from annual reports, periods 2021-12-31 to 2024-12-31: revenue went from 4,933,118,000 EUR (2021-12-31) to 7,212,382,000 EUR (2024-12-31), a change of +46.2%; net income (loss) went from 265,327,000 EUR (2021-12-31) to 212,806,000 EUR (2024-12-31), a change of -19.8%; total assets went from 19,233,835,000 EUR (2021-12-31) to 21,405,241,000 EUR (2024-12-31), a change of +11.3%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 1438569, tags Assets, ProfitLoss, Revenue; 4 periods shown, dashes mark figures Grifols SA did not tag for that period.

Analyst ratings, price targets and “bullish” or “bearish” calls on Grifols SA (CIK 1438569) are third-party opinions that the SEC does not publish or check. What the regulator does hold are the facts those views are built on, and the most recent 20-F annual report was filed 2026-04-17. Comparing any rating with those primary documents shows whether the thesis matches what the company itself reported.

Current reports. Of the 349 8-K or 6-K reports in Grifols SA’s recent EDGAR index, the 4 listed here run from 2026-06-18 to 2026-07-30, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 1438569 is on the EDGAR company page; the latest 20-F there is dated 2026-04-17 and the oldest filing in the recent index dates from 2008-10-20. Insider trades for Grifols SA appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Helport ai company news october 2026

For “Helport ai company news october 2026”, the matching SEC registrant is Helport AI Ltd, which trades as HPAI, HPAIW and files under Central Index Key 2001699. EDGAR puts it in the “Services-Prepackaged Software” industry code with an unstated jurisdiction as its state or country of incorporation. Data below comes straight from EDGAR as checked on Oct 25, 2026, where the latest item is a 6-K filed 2026-07-10 (this view begins at filings dated on or before 2025-04-18), across 62 filings on record. This is reference material, not trading advice.

More of the filing record for Helport AI Ltd (CIK 2001699), filings 2024-12-11 to 2025-01-06: 424B3 on 2025-01-06; EFFECT on 2024-12-26; CORRESP on 2024-12-23; F-1 on 2024-12-23; UPLOAD on 2024-12-11. Each form type has a fixed purpose under SEC rules, so the mix shows what kind of events the company has been reporting.

Updated Oct 25, 2026 ET

Hemab therapeutics ceo latest announcement

For “Hemab therapeutics ceo latest announcement”, the matching SEC registrant is Hemab Therapeutics Holdings, Inc., which trades as COAG and files under Central Index Key 2114044. EDGAR puts it in the “Biological Products, (No Diagnostic Substances)” industry code with DE as its state or country of incorporation. Data below comes straight from EDGAR as checked on Oct 25, 2026, where the latest item is a 4 filed 2026-09-25, across 50 filings on record. This is reference material, not trading advice.

More of the filing record for Hemab Therapeutics Holdings, Inc. (CIK 2114044), filings 2026-06-17 to 2026-08-11: 10-Q on 2026-08-11; SCHEDULE 13G on 2026-08-07; SCHEDULE 13G on 2026-08-06; SCHEDULE 13G on 2026-08-05; 4 on 2026-06-17. Each form type has a fixed purpose under SEC rules, so the mix shows what kind of events the company has been reporting.

Updated Oct 25, 2026 ET

Hyperion defi hypd news

For “Hyperion defi hypd news”, the matching SEC registrant is HYPERION DEFI, INC., which trades as HYPD and files under Central Index Key 1682639. EDGAR puts it in the “Finance Services” industry code with DE as its state or country of incorporation; its earlier registered name was EYENOVIA, INC. Data below comes straight from EDGAR as checked on Oct 25, 2026, where the latest item is a SCHEDULE 13G/A filed 2026-10-05, across 612 filings on record. This is reference material, not trading advice.

The information contained on, or that can be accessed through, our website is not a part of this report. We have included our website address in this report solely as an inactive textual reference. Disclaimer Certain information contained in this Item 1 relate to or are based on studies, publications, surveys and other data obtained from third-party sources and Hyperion DeFi’s own internal estimates and research. While Hyperion DeFi believes these third-party studies, publications, surveys and other data to be reliable as of the date of this report, it has not independently verified, and makes no representation as to, the adequacy, fairness, accuracy or completeness of any information obtained from third-party sources.

Updated Oct 25, 2026 ET

Immuneering corporation bullish and bearish analyst opinions

For “Immuneering corporation bullish and bearish analyst opinions”, the matching SEC registrant is Immuneering Corp, which trades as IMRX and files under Central Index Key 1790340. EDGAR puts it in the “Pharmaceutical Preparations” industry code with DE as its state or country of incorporation. Data below comes straight from EDGAR as checked on Oct 25, 2026, where the latest item is a 10-Q filed 2026-08-05, across 320 filings on record. This is reference material, not trading advice.

Business description, quoted from the 10-K filed 2026-03-06 by Immuneering Corp (CIK 1790340) — source document:

We are a late-stage clinical oncology company focused on keeping cancer patients alive and helping them thrive . We are developing and seeking to commercialize an entirely new category of anti-cancer medicines, Deep Cyclic Inhibitors, which we believe have the potential to be more effective and better tolerated targeted therapies. Deep Cyclic Inhibitors Deep Cyclic Inhibition® ("DCI") is a novel mechanism that aims to deprive tumor cells of the sustained proliferative signaling required for rapid growth, while sparing healthy cells through a cadenced, normalized level of signaling. Our Deep Cyclic Inhibitors inhibit clinically-validated core signaling pathways, such as the mitogen-activated protein kinase ("MAPK") pathway. Our novel approach is designed to improve durability and tolerability, and differentiates us from chronically targeted precision therapies, which are generally limited by toxicity, resistance and/or application to specific mutations only . Atebimetinib (IMM-1-104) Our lead product candidate, atebimetinib (IMM-1-104), is an oral, once-daily Deep Cyclic Inhibitor of mitogen-activated protein kinase kinase (" MEK"), designed to improve durability and tolerability across many cancer indications, including MAPK pathway-driven tumors such as pancreatic cancer.

Financial trend for Immuneering Corp from annual reports, periods 2022-12-31 to 2025-12-31: revenue went from $316,952 (2022-12-31) to $0 (2023-12-31), a change of -100.0%; net income (loss) went from -$50.51 million (2022-12-31) to -$56.02 million (2025-12-31), a change of -10.9%; total assets went from $122.37 million (2022-12-31) to $231.99 million (2025-12-31), a change of +89.6%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 1790340, tags Assets, NetIncomeLoss, Revenues; 4 periods shown, dashes mark figures Immuneering Corp did not tag for that period.

Analyst ratings, price targets and “bullish” or “bearish” calls on Immuneering Corp (CIK 1790340) are third-party opinions that the SEC does not publish or check. What the regulator does hold are the facts those views are built on: the latest results release filed under 8-K Item 2.02 is dated 2026-08-05, and the most recent 10-K annual report was filed 2026-03-06. Comparing any rating with those primary documents shows whether the thesis matches what the company itself reported.

Current reports. Of the 45 8-K or 6-K reports in Immuneering Corp’s recent EDGAR index, the 4 listed here run from 2026-06-01 to 2026-08-05, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 1790340 is on the EDGAR company page; the latest 10-K there is dated 2026-03-06 and the oldest filing in the recent index dates from 2019-10-04. Insider trades for Immuneering Corp appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Immuron limited bullish and bearish analyst opinions

For “Immuron limited bullish and bearish analyst opinions”, the matching SEC registrant is Immuron Ltd, which trades as IMRN and files under Central Index Key 1660046. EDGAR puts it in the “Pharmaceutical Preparations” industry code with Australia as its state or country of incorporation. Data below comes straight from EDGAR as checked on Oct 25, 2026, where the latest item is a 6-K filed 2026-10-23, across 425 filings on record. This is reference material, not trading advice.

Business description, quoted from the 20-F filed 2026-09-24 by Immuron Ltd (CIK 1660046) — source document:

OPERATING AND FINANCIAL REVIEW AND PROSPECTS 39 A. Operating Results 39 B. Liquidity and Capital Resources 43 C. Research and Development, Patents and Licenses 46 D. Trend Information 47 E Critical Accounting Estimates 47 ITEM 6. DIRECTORS, SENIOR MANAGEMENT AND EMPLOYEES 48 A. Directors and Senior Management 48 B. Compensation 50 C. Board Practices 61 D. Employees 62 E. Share Ownership 63 F. Disclosure of a Registrant’s Action to Recover Erroneously Awarded Compensation 63 ITEM 7. MAJOR SHAREHOLDERS AND RELATED PARTY TRANSACTIONS 64 A. Major Shareholders 64 B. Related Party Transactions 64 C. Interests of Experts and Counsel 65 ITEM 8. FINANCIAL INFORMATION 65 A. Financial Statements and Other Financial Information 65 B. Significant Changes 65 ITEM 9.

Financial trend for Immuron Ltd from annual reports, periods 2022-06-30 to 2025-06-30: revenue went from 765,193 AUD (2022-06-30) to 7,287,002 AUD (2025-06-30), a change of +852.3%; net income (loss) went from -2,854,254 AUD (2022-06-30) to -5,215,987 AUD (2025-06-30), a change of -82.7%; total assets went from 24,855,824 AUD (2022-06-30) to 10,129,842 AUD (2025-06-30), a change of -59.2%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 1660046, tags Assets, ProfitLoss, Revenue; 4 periods shown, dashes mark figures Immuron Ltd did not tag for that period.

Analyst ratings, price targets and “bullish” or “bearish” calls on Immuron Ltd (CIK 1660046) are third-party opinions that the SEC does not publish or check. What the regulator does hold are the facts those views are built on, and the most recent 20-F annual report was filed 2026-09-24. Comparing any rating with those primary documents shows whether the thesis matches what the company itself reported.

Current reports. Of the 325 8-K or 6-K reports in Immuron Ltd’s recent EDGAR index, the 4 listed here run from 2026-10-13 to 2026-10-23, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 1660046 is on the EDGAR company page; the latest 20-F there is dated 2026-09-24 and the oldest filing in the recent index dates from 2016-12-21. Insider trades for Immuron Ltd appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Ingevity corporation bullish and bearish analyst opinions

For “Ingevity corporation bullish and bearish analyst opinions”, the matching SEC registrant is Ingevity Corp, which trades as NGVT and files under Central Index Key 1653477. EDGAR puts it in the “Chemicals & Allied Products” industry code with DE as its state or country of incorporation. Data below comes straight from EDGAR as checked on Oct 25, 2026, where the latest item is a 4 filed 2026-10-02, across 658 filings on record. This is reference material, not trading advice.

Business description, quoted from the 10-K filed 2026-02-26 by Ingevity Corp (CIK 1653477) — source document:

Ingevity Corporation provides products and technologies that purify, protect, and enhance the world around us. Through a diverse team of talented and experienced people, we develop, manufacture, and bring to market solutions that are largely renewably sourced and help customers solve complex problems while making the world more sustainable. Our products are used in a variety of demanding applications, including automotive gasoline vapor emissions control systems, food, water and chemical filtration, asphalt paving, agrochemical dispersants, bioplastics, coatings, elastomers, and paint for road markings. We operate in three reportable segments: Performance Materials, Performance Chemicals and Advanced Polymer Technologies. Throughout this Annual Report on Form 10-K, except where otherwise stated or indicated by the context, "Ingevity," the "Company," "we," "us," or "our" means Ingevity Corporation and its consolidated subsidiaries and their predecessors.

Financial trend for Ingevity Corp from annual reports, periods 2022-12-31 to 2025-12-31: revenue went from $1.67 billion (2022-12-31) to $1.17 billion (2025-12-31), a change of -30.0%; net income (loss) went from $211.60 million (2022-12-31) to -$167.10 million (2025-12-31), a change of -179.0%; total assets went from $2.74 billion (2022-12-31) to $1.65 billion (2025-12-31), a change of -39.7%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 1653477, tags Assets, NetIncomeLoss, RevenueFromContractWithCustomerExcludingAssessedTax; 4 periods shown, dashes mark figures Ingevity Corp did not tag for that period.

Analyst ratings, price targets and “bullish” or “bearish” calls on Ingevity Corp (CIK 1653477) are third-party opinions that the SEC does not publish or check. What the regulator does hold are the facts those views are built on: the latest results release filed under 8-K Item 2.02 is dated 2026-07-29, and the most recent 10-K annual report was filed 2026-02-26. Comparing any rating with those primary documents shows whether the thesis matches what the company itself reported.

Current reports. Of the 115 8-K or 6-K reports in Ingevity Corp’s recent EDGAR index, the 4 listed here run from 2026-05-04 to 2026-07-29, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 1653477 is on the EDGAR company page; the latest 10-K there is dated 2026-02-26 and the oldest filing in the recent index dates from 2015-10-06. Insider trades for Ingevity Corp appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Intellicheck, inc. bullish and bearish analyst opinions

For “Intellicheck, inc. bullish and bearish analyst opinions”, the matching SEC registrant is Intellicheck, Inc., which trades as IDN and files under Central Index Key 1040896. EDGAR puts it in the “Services-Prepackaged Software” industry code with DE as its state or country of incorporation; its earlier registered name was Intellicheck Mobilisa, Inc. Data below comes straight from EDGAR as checked on Oct 25, 2026, where the latest item is a 4 filed 2026-10-13, across 1000 filings on record. This is reference material, not trading advice.

Business description, quoted from the 10-K filed 2026-03-19 by Intellicheck, Inc. (CIK 1040896) — source document:

We originally were incorporated in the state of New York in 1994 as Intelli-Check, Inc. In August 1999, we reincorporated in Delaware. On March 14, 2008, our corporation was renamed Intelli-Check - Mobilisa, Inc. after the consummation of the merger with Mobilisa, Inc. (“Mobilisa”) (references to “Intelli-Check” in this annual report refer to the Company prior to the merger with Mobilisa). At the closing of the merger, our headquarters were moved to Mobilisa’s offices in Port Townsend, Washington. On October 27, 2009, we made a further change in our name to Intellicheck Mobilisa, Inc. On May 4, 2017, with the approval of our shareholders, we changed our name to Intellicheck, Inc. (“Intellicheck,” “we,” “our,” “us,” or “the Company”).

Financial trend for Intellicheck, Inc. from annual reports, periods 2022-12-31 to 2025-12-31: net income (loss) went from -$4.16 million (2022-12-31) to $1.27 million (2025-12-31), a change of +130.6%; total assets went from $22.45 million (2022-12-31) to $24.48 million (2025-12-31), a change of +9.0%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 1040896, tags Assets, NetIncomeLoss, Revenues; 4 periods shown, dashes mark figures Intellicheck, Inc. did not tag for that period.

Analyst ratings, price targets and “bullish” or “bearish” calls on Intellicheck, Inc. (CIK 1040896) are third-party opinions that the SEC does not publish or check. What the regulator does hold are the facts those views are built on: the latest results release filed under 8-K Item 2.02 is dated 2026-08-13, and the most recent 10-K annual report was filed 2026-03-19. Comparing any rating with those primary documents shows whether the thesis matches what the company itself reported.

Current reports. Of the 148 8-K or 6-K reports in Intellicheck, Inc.’s recent EDGAR index, the 4 listed here run from 2026-05-12 to 2026-08-13, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 1040896 is on the EDGAR company page; the latest 10-K there is dated 2026-03-19 and the oldest filing in the recent index dates from 2007-08-15. Insider trades for Intellicheck, Inc. appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Intercure ltd. bullish and bearish analyst opinions

For “Intercure ltd. bullish and bearish analyst opinions”, the matching SEC registrant is Intercure Ltd., which trades as INCR and files under Central Index Key 1857030. EDGAR puts it in the “Pharmaceutical Preparations” industry code with Israel as its state or country of incorporation. Data below comes straight from EDGAR as checked on Oct 25, 2026, where the latest item is a 6-K filed 2026-09-08, across 119 filings on record. This is reference material, not trading advice.

Business description, quoted from the 20-F filed 2026-04-30 by Intercure Ltd. (CIK 1857030) — source document:

OPERATING AND FINANCIAL REVIEW AND PROSPECTS. 65 A. Operating Results. 65 B. Liquidity and Capital Resources. 69 C. Research and Development. 71 D. Trend Information. 71 E. Critical Accounting Estimates. 71 ITEM 6. DIRECTORS, SENIOR MANAGEMENT AND EMPLOYEES. 72 A. Directors and Senior Management. 72 B. Compensation. 73 C. Board Practices. 77 D. Employees. 90 E. Share Ownership. 90 F. Disclosure of a Registrant’s Action to Recover Erroneously Awarded Compensation 91 ITEM 7. MAJOR SHAREHOLDERS AND RELATED PARTY TRANSACTIONS. 91 A. Major Shareholders. 91 B. Related Party Transactions. 93 C. Interests of Experts and Counsel. 93 ITEM 8. FINANCIAL INFORMATION. 94 A. Consolidated Statements and Other Financial Information. 94 B. Significant Changes. 96 ITEM 9.

Financial trend for Intercure Ltd. from annual reports, periods 2021-12-31 to 2024-12-31: revenue went from 219,677,000 ILS (2021-12-31) to 238,845,000 ILS (2024-12-31), a change of +8.7%; net income (loss) went from 7,293,000 ILS (2021-12-31) to -72,793,000 ILS (2024-12-31), a change of -1098.1%; total assets went from 696,545,000 ILS (2021-12-31) to 762,574,000 ILS (2024-12-31), a change of +9.5%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 1857030, tags Assets, ProfitLoss, Revenue; 4 periods shown, dashes mark figures Intercure Ltd. did not tag for that period.

Analyst ratings, price targets and “bullish” or “bearish” calls on Intercure Ltd. (CIK 1857030) are third-party opinions that the SEC does not publish or check. What the regulator does hold are the facts those views are built on, and the most recent 20-F annual report was filed 2026-04-30. Comparing any rating with those primary documents shows whether the thesis matches what the company itself reported.

Current reports. Of the 69 8-K or 6-K reports in Intercure Ltd.’s recent EDGAR index, the 4 listed here run from 2026-08-11 to 2026-09-08, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 1857030 is on the EDGAR company page; the latest 20-F there is dated 2026-04-30 and the oldest filing in the recent index dates from 2021-04-21. Insider trades for Intercure Ltd. appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Kala bio, inc. bullish and bearish analyst opinions

For “Kala bio, inc. bullish and bearish analyst opinions”, the matching SEC registrant is KALA BIO, Inc., which trades as KALA and files under Central Index Key 1479419. EDGAR puts it in the “Pharmaceutical Preparations” industry code with DE as its state or country of incorporation; its earlier registered name was KALA BIO, Inc. Data below comes straight from EDGAR as checked on Oct 25, 2026, where the latest item is a SCHEDULE 13G filed 2026-10-19, across 674 filings on record. This is reference material, not trading advice.

Business description, quoted from the 10-K filed 2026-04-15 by KALA BIO, Inc. (CIK 1479419) — source document:

In this Annual Report on Form 10-K, unless the context otherwise requires, references to “we,” “us,” “our,” “our company,” “KALA,” “KALA BIO” and “Company” refer to KALA BIO, Inc. and its subsidiaries. ​ Overview We are a biopharmaceutical company in transition, evaluating the development of a dedicated, on-premises artificial intelligence (AI) infrastructure platform for the biotechnology industry. Our current focus is leveraging our mesenchymal stem cell secretome (“MSC-S”) platform to test development of a scalable AI platform-as-a-service business to deploy secure, purpose-built AI systems directly within biotech and pharmaceutical client environments. We have historically been engaged in the research, development and commercialization of innovative therapies for rare and severe diseases of the front and back of the eye.

Financial trend for KALA BIO, Inc. from annual reports, periods 2022-12-31 to 2025-12-31: net income (loss) went from -$44.82 million (2022-12-31) to -$26.98 million (2025-12-31), a change of +39.8%; total assets went from $86.82 million (2022-12-31) to $9.49 million (2025-12-31), a change of -89.1%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 1479419, tags Assets, NetIncomeLoss, Revenues; 4 periods shown, dashes mark figures KALA BIO, Inc. did not tag for that period.

Analyst ratings, price targets and “bullish” or “bearish” calls on KALA BIO, Inc. (CIK 1479419) are third-party opinions that the SEC does not publish or check. What the regulator does hold are the facts those views are built on: the latest results release filed under 8-K Item 2.02 is dated 2025-08-08, and the most recent 10-K annual report was filed 2026-04-15. Comparing any rating with those primary documents shows whether the thesis matches what the company itself reported.

Current reports. Of the 122 8-K or 6-K reports in KALA BIO, Inc.’s recent EDGAR index, the 4 listed here run from 2026-07-23 to 2026-09-10, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 1479419 is on the EDGAR company page; the latest 10-K there is dated 2026-04-15 and the oldest filing in the recent index dates from 2009-12-23. Insider trades for KALA BIO, Inc. appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Knightscope kscp october 2026 news

For “Knightscope kscp october 2026 news”, the matching SEC registrant is Knightscope, Inc., which trades as KSCP and files under Central Index Key 1600983. EDGAR puts it in the “Communications Equipment, NEC” industry code with DE as its state or country of incorporation. Data below comes straight from EDGAR as checked on Oct 25, 2026, where the latest item is a 8-K filed 2026-10-20, across 295 filings on record. This is reference material, not trading advice.

Security buyers frequently expect the presence of licensed personnel as part of a comprehensive security program, and our model is designed to align with those expectations while incorporating automation and AI-driven technologies. ​ Recent Developments ​ On February 27, 2026, we completed the acquisition (the “Event Risk Acquisition”) of all the issued and outstanding membership interest of Event Risk LLC, an Indiana limited liability company (“Event Risk”) pursuant to a Securities Purchase Agreement (the “Event Risk Agreement”). As a result of the transaction, Event Risk became a wholly owned subsidiary of the Company.

Updated Oct 25, 2026 ET

Kscp sec filing october 2026 knightscope

For “Kscp sec filing october 2026 knightscope”, the matching SEC registrant is Knightscope, Inc., which trades as KSCP and files under Central Index Key 1600983. EDGAR puts it in the “Communications Equipment, NEC” industry code with DE as its state or country of incorporation. Data below comes straight from EDGAR as checked on Oct 25, 2026, where the latest item is a 8-K filed 2026-10-20 (this view begins at filings dated on or before 2026-06-09), across 295 filings on record. This is reference material, not trading advice.

Knightscope, Inc. has 295 filings in its recent EDGAR index, including 5 annual reports and 15 quarterly reports; its newest filing is a 8-K from 2026-10-20.

Updated Oct 25, 2026 ET

Mangoceuticals, inc. bullish and bearish analyst opinions

For “Mangoceuticals, inc. bullish and bearish analyst opinions”, the matching SEC registrant is MANGOCEUTICALS, INC., which trades as MGRX and files under Central Index Key 1938046. EDGAR puts it in the “Services-Misc Health & Allied Services, NEC” industry code with TX as its state or country of incorporation; its earlier registered name was MANGOCEUTICALS, INC. Data below comes straight from EDGAR as checked on Oct 25, 2026, where the latest item is a 8-K filed 2026-10-09, across 240 filings on record. This is reference material, not trading advice.

Business description, quoted from the 10-K filed 2026-04-01 by MANGOCEUTICALS, INC. (CIK 1938046) — source document:

The information included in this Report on Form 10-K should be read in conjunction with the consolidated financial statements and related notes in “ Item 8. Financial Statements and Supplemental Data ” of this Report. Our logo and some of our trademarks and tradenames are used in this Report. This Report also includes trademarks, tradenames and service marks that are the property of others. Solely for convenience, trademarks, tradenames, and service marks referred to in this Report may appear without the ®, ™ and SM symbols. References to our trademarks, tradenames and service marks are not intended to indicate in any way that we will not assert to the fullest extent under applicable law our rights or the rights of the applicable licensors if any, nor that respective owners to other intellectual property rights will not assert, to the fullest extent under applicable law, their rights thereto.

Financial trend for MANGOCEUTICALS, INC. from annual reports, periods 2022-12-31 to 2025-12-31: revenue went from $8,939 (2022-12-31) to $456,021 (2025-12-31), a change of +5001.5%; net income (loss) went from -$2.00 million (2022-12-31) to -$20.64 million (2025-12-31), a change of -933.2%; total assets went from $1.00 million (2022-12-31) to $16.09 million (2025-12-31), a change of +1503.7%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 1938046, tags Assets, NetIncomeLoss, Revenues; 4 periods shown, dashes mark figures MANGOCEUTICALS, INC. did not tag for that period.

Analyst ratings, price targets and “bullish” or “bearish” calls on MANGOCEUTICALS, INC. (CIK 1938046) are third-party opinions that the SEC does not publish or check. What the regulator does hold are the facts those views are built on: the latest results release filed under 8-K Item 2.02 is dated 2024-08-15, and the most recent 10-K annual report was filed 2026-04-01. Comparing any rating with those primary documents shows whether the thesis matches what the company itself reported.

Current reports. Of the 78 8-K or 6-K reports in MANGOCEUTICALS, INC.’s recent EDGAR index, the 4 listed here run from 2026-08-04 to 2026-10-09, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 1938046 is on the EDGAR company page; the latest 10-K there is dated 2026-04-01 and the oldest filing in the recent index dates from 2022-08-31. Insider trades for MANGOCEUTICALS, INC. appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Mastercard world legend itaú personnalité

A card-product query combining Mastercard’s World Legend tier with Itaú Personnalité, the premium segment of Brazil’s Itaú Unibanco; only Mastercard is a U.S. domestic filer.

For “Mastercard world legend itaú personnalité”, the matching SEC registrant is Mastercard Inc, which trades as MA and files under Central Index Key 1141391. EDGAR puts it in the “Services-Business Services, NEC” industry code with DE as its state or country of incorporation. Data below comes straight from EDGAR as checked on Oct 25, 2026, where the latest item is a 4 filed 2026-10-19, across 1000 filings on record. This is reference material, not trading advice.

Business description, quoted from the 10-K filed 2026-02-11 by Mastercard Inc (CIK 1141391) — source document:

Mastercard is a technology company in the global payments industry. We connect consumers, financial institutions, merchants, governments, digital partners, businesses and other organizations worldwide by enabling electronic payments and making those payment transactions secure, simple, smart and accessible. We make payments easier and more efficient by providing a wide range of payment solutions and services using our family of well-known and trusted brands, including our primary brand Mastercard®, as well as our Maestro® and Cirrus® brands. We operate a payments network that provides choice and flexibility for consumers, merchants and our customers. Through our unique and proprietary global payments network, we switch (authorize, clear and settle) payment transactions. We have additional payments capabilities that include automated clearing house (“ACH”) transactions (both batch and real-time account-based payments).

Financial trend for Mastercard Inc from annual reports, periods 2022-12-31 to 2025-12-31: revenue went from $22.24 billion (2022-12-31) to $32.79 billion (2025-12-31), a change of +47.5%; total assets went from $38.72 billion (2022-12-31) to $54.16 billion (2025-12-31), a change of +39.9%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 1141391, tags Assets, NetIncomeLoss, Revenues; 4 periods shown, dashes mark figures Mastercard Inc did not tag for that period.

Mastercard Inc has 1000 filings in its recent EDGAR index, including 7 annual reports and 23 quarterly reports; its newest filing is a 4 from 2026-10-19.

Current reports. Of the 85 8-K or 6-K reports in Mastercard Inc’s recent EDGAR index, the 4 listed here run from 2026-06-02 to 2026-07-30, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 1141391 is on the EDGAR company page; the latest 10-K there is dated 2026-02-11 and the oldest filing in the recent index dates from 2019-04-03. Insider trades for Mastercard Inc appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Matador resources mtdr latest news october 2026

For “Matador resources mtdr latest news october 2026”, the matching SEC registrant is Matador Resources Co, which trades as MTDR and files under Central Index Key 1520006. EDGAR puts it in the “Crude Petroleum & Natural Gas” industry code with TX as its state or country of incorporation. Data below comes straight from EDGAR as checked on Oct 25, 2026, where the latest item is a 8-K filed 2026-10-21, across 1000 filings on record. This is reference material, not trading advice.

Business description, quoted from the 10-K filed 2026-02-26 by Matador Resources Co (CIK 1520006) — source document:

For certain oil and natural gas terms used in this Annual Report, see the “Glossary of Oil and Natural Gas Terms” included in this Annual Report. General We are an independent energy company engaged in the exploration, development, production and acquisition of oil and natural gas resources in the United States, with an emphasis on oil and natural gas shale and other unconventional plays. Our current operations are focused primarily on the oil and liquids-rich portion of the Wolfcamp and Bone Spring plays in the Delaware Basin in Southeast New Mexico and West Texas. We also have operations in the Haynesville shale and Cotton Valley plays in Northwest Louisiana. Additionally, we conduct midstream operations in support of, and to provide flow assurance for, our exploration, development and production operations and provide natural gas processing, oil transportation services, oil, natural gas and produced water gathering services and produced water disposal services to third parties.

Financial trend for Matador Resources Co from annual reports, periods 2022-12-31 to 2025-12-31: revenue went from $3.06 billion (2022-12-31) to $3.70 billion (2025-12-31), a change of +20.9%; net income (loss) went from $1.21 billion (2022-12-31) to $759.22 million (2025-12-31), a change of -37.5%; total assets went from $5.55 billion (2022-12-31) to $11.71 billion (2025-12-31), a change of +110.8%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 1520006, tags Assets, NetIncomeLoss, Revenues; 4 periods shown, dashes mark figures Matador Resources Co did not tag for that period.

For the latest news, the fastest official source is the filing feed: Matador Resources Co (CIK 1520006) filed 177 current reports (8-K or 6-K) in its recent EDGAR window, the newest on 2026-10-21, and its overall latest filing is a 8-K dated 2026-10-21. Companies must file an 8-K within four business days of most material events.

Current reports. Of the 177 8-K or 6-K reports in Matador Resources Co’s recent EDGAR index, the 4 listed here run from 2026-08-05 to 2026-10-21, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 1520006 is on the EDGAR company page; the latest 10-K there is dated 2026-02-26 and the oldest filing in the recent index dates from 2017-02-23. Insider trades for Matador Resources Co appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Mcdonald's starbucks global korea sales stores packaging latest news

Two restaurant chains searched for Korea sales, store and packaging news; Starbucks Korea is operated by a licensee rather than directly by Starbucks. Filing records below were read from EDGAR on Oct 25, 2026, one registrant per row.

MCDONALDS CORP (MCD; retail-eating places, incorporated in DE) — recent current reports: the 8-K of 2026-09-23 covering 7.01 (regulation fd disclosure), 9.01 (financial statements and exhibits); the 8-K of 2026-08-04 covering 5.02 (departure/election of directors or officers), 7.01 (regulation fd disclosure), 9.01 (financial statements and exhibits). Year to 2025-12-31: revenue of $26.89 billion, net income (loss) $8.56 billion (10-K, 2026-02-24).

STARBUCKS CORP (SBUX; retail-eating & drinking places, incorporated in WA) — recent current reports: the 8-K of 2026-09-24 covering 2.05 (costs associated with exit or disposal activities), 7.01 (regulation fd disclosure); the 8-K of 2026-07-29 covering 2.02 (results of operations and financial condition), 9.01 (financial statements and exhibits). Year to 2025-09-28: revenue of $37.18 billion, net income (loss) $1.86 billion (10-K, 2025-11-14).

How often each filed an 8-K under Item 2.01, completion of an acquisition or disposition of assets: MCD 0, SBUX 2 (latest 2018-08-28).

In South Korea both brands are run through local partners: Starbucks Korea is operated by SCK Company, part of the Shinsegae group, while McDonald’s does not break out Korea in its segment reporting. Korea-specific sales, store counts or packaging changes therefore come mainly from those operators and Korean filings on the DART system rather than from the U.S. parents’ SEC reports.

Merck mrk sec filing oncology october 2026

For “Merck mrk sec filing oncology october 2026”, the matching SEC registrant is Merck & Co., Inc., which trades as MRK and files under Central Index Key 310158. EDGAR puts it in the “Pharmaceutical Preparations” industry code with NJ as its state or country of incorporation; its earlier registered name was Merck & Co. Inc. Data below comes straight from EDGAR as checked on Oct 25, 2026, where the latest item is a 3/A filed 2026-10-22, across 1002 filings on record. This is reference material, not trading advice.

Business description, quoted from the 10-K filed 2026-02-24 by Merck & Co., Inc. (CIK 310158) — source document:

The Pharmaceutical segment includes human health pharmaceutical and vaccine products. Human health pharmaceutical products consist of therapeutic and preventive agents, generally sold by prescription, for the treatment of human disorders. The Company sells these human health pharmaceutical products primarily to drug wholesalers and retailers, hospitals, government agencies, and managed health care providers such as health maintenance organizations, pharmacy benefit managers and other institutions. Human health vaccine products consist of preventive pediatric, adolescent and adult vaccines. The Company sells these human health vaccines primarily to physicians, wholesalers, distributors and government entities. The Animal Health segment discovers, develops, manufactures and markets a wide range of veterinary pharmaceutical and vaccine products, as well as health management solutions and services, for the prevention, treatment and control of disease in all major livestock and companion animal species.

Financial trend for Merck & Co., Inc. from annual reports, periods 2022-12-31 to 2025-12-31: revenue went from $59.28 billion (2022-12-31) to $65.01 billion (2025-12-31), a change of +9.7%; net income (loss) went from $14.52 billion (2022-12-31) to $18.25 billion (2025-12-31), a change of +25.7%; total assets went from $109.16 billion (2022-12-31) to $136.87 billion (2025-12-31), a change of +25.4%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 310158, tags Assets, NetIncomeLoss, Revenues; 4 periods shown, dashes mark figures Merck & Co., Inc. did not tag for that period.

Merck & Co., Inc. has 1002 filings in its recent EDGAR index, including 8 annual reports and 25 quarterly reports; its newest filing is a 3/A from 2026-10-22.

Current reports. Of the 67 8-K or 6-K reports in Merck & Co., Inc.’s recent EDGAR index, the 4 listed here run from 2026-05-22 to 2026-10-13, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 310158 is on the EDGAR company page; the latest 10-K there is dated 2026-02-24 and the oldest filing in the recent index dates from 2018-05-29. Insider trades for Merck & Co., Inc. appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET